Terpene-enriched cannabinoid product for women health

Abstract

A product for treating conditions and / or symptoms associated with women health is described, which product comprises at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non- terpene, carrier, optionally at least three secondary terpenes, and optionally at least one phytoestrogen; wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in said product is about 0.1 to about 1.0. Also described is the above product wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight / weight ratio in said compositions is about 0.05 to about 1.0, forming a terpene-enriched product with an enhanced therapeutic effect in treating conditions and / or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and / or disorders, menstrual cycle, hormonal deficiency and / or hormonal imbalance, compared with that of a product comprising the same cannabinoids amounts and one half the amount of said primary terpene.

Description

DEMANDE OU BREVET VOLUMINEUX LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME. CECI EST LE TOME 1 DE 2 CONTENANT LES PAGES 1 À 160 NOTE: Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS / PATENTS THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE THAN ONE VOLUME THIS IS VOLUME 1 OF 2 CONTAINING PAGES 1 TO 160 NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME : NOTE POUR LE TOME / VOLUME NOTE: Title of the Invention TERPENE-ENRICHED CANNABINOID PRODUCT FOR WOMEN HEALTH Field of the Invention

[003] The field of art to which this invention generally pertains is terpenes-enriched products, and specifically terpenes-enriched products for therapeutic use. Background of the invention

[004] Menopause represents the transition of a woman from a reproductive to non- reproductive state as a result of a major reduction in female hormonal production by the ovaries. The transition is a natural process or may be the result of surgical intervention (removal of the ovaries) or the result of therapeutic regiment (e.g., administration of hormonal therapy for the treatment of patients with early stage breast cancer).

[005] A diminished level of estrogen, the female hormone, has a direct effect on the hypothalamus, the part of the brain responsible for controlling appetite, sleep cycles, sex hormones, and body temperature.

[006] Thus, menopause may be manifested by various conditions and / or symptoms, including hot flashes, facial flushing, night sweat, osteoporosis, fatigue, irritability, insomnia and sleep disorder, inability to concentrate, depression, memory loss, headache, anxiety, nervousness, muscle tension, myalgia, intermittent dizziness, paresthesia, indigestion, palpitations, tachycardia, nausea, constipation, diarrhea, arthralgia and / or arthritis, pelvic pain, spasms, cramps, paresthesia, Polycystic Ovary Syndrome (POCS), premenstrual syndrome (PMS), premenstrual tension, premenstrual dysphoric disorder (PMDD), cold hands and feet, weight gain, mental awareness problems, sexual pain disorder, dyspareunia breast pain and / or mastalgia, menopausal skin, inflammation, oxidative stress, cardiovascular disease, loss of pelvic muscle tone, urinary incontinence, vaginal dryness, vaginal infections, human papillomavirus (HPV), Uterine Fibroid, cystitis, women hormonal irregularity, irregular periods, reduced libido, hair loss and / or thinning, age-related winkles, brittle nails, gam disorders, irregular body odor. Menopausal conditions and / or symptoms affect about 70% of women approaching menopause. Typical menopause conditions and / or symptoms last for the whole menopause transition, but some women may experience them for the rest of their lives.

[007] Hormone therapies such as estrogen therapy, progesterone therapy or estrogen- progesterone combinations have proven most effective. However, there are definite risks to hormone therapy such as increased risk of breast cancer, stroke and heart disease. Accordingly, it would be highly desirable to provide a treatment for improving menopausal related conditions and / or symptoms which do not cause debilitating side effects. This invention relates to methods for improving women health and reducing menopausal conditions and / or symptoms via natural components available in Cannabis.

[008] Terpenes play important roles in cannabinoids-comprising products, affecting the functionality and bioavailability of the cannabinoids and the aroma of the product. Processing cannabis plant material typically leads to terpenes loss so that most of cannabis products are of relatively low terpene content. That is particularly true for cannabis extracts and products thereof, such as cannabis tablets, cannabis gel capsules, cannabis patches, cannabis suppositories, etc. Most cannabis terpenes boiling points are in the range between about 150°C and about 220°C and they evaporate, at least partially, during cannabis buds drying, during solvent separation from extracts and during decarboxylation. Monoterpenes are lost at a rate greater than that of terpenes with a higher molecular weight and terpenes carrying no hydroxyl groups are lost at a rate greater than that of terpenes that do carry hydroxyl groups. Summary of the Invention

[009] According to an embodiment, provided is a product for treating conditions and / or symptoms associated with women health comprising (i) at least one cannabinoid in a specific amount, (ii) a primary terpene in a specific amount, (iii) at least 5% by weight of a non- cannabinoid, non-terpene, carrier, (iv) optionally at least three secondary terpenes, (v) optionally at least one phytoestrogen; and (a) wherein the non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in the product is about 0.1 to about 1.0, or (b) wherein the non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight / weight ratio in the product is 0.05 to about 1.0, forming a terpene-enriched product with an enhanced therapeutic effect in treating conditions and / or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and / or disorders, menstrual cycle, hormonal deficiency and / or hormonal imbalance, compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene.

[0010] According to an embodiment, said product is selected from the group consisting of tablets, gel capsules, medical patches, topicals, creams, varnishes, sublingual oils, sprays, edibles, suppositories, tampons, rectal candles, cigarettes, vaporizer liquids nasal preparartion, preparations containing micro and nano-emulsions, preparations containing micro and nano- particles and combinations thereof.

[0011] According to an embodiment, the enhanced therapeutic effect comprises a shortened onset time, increased magnitude, extended duration, reduced dosages, reduced secondary adverse symptoms, reduced frequency of conditions and / or symptoms, reduced severity of conditions and / or symptoms, reduce consumption of other drugs and combinations thereof.

[0012] According to an embodiment, the conditions and / or symptoms are selected from the group consisting of hot flashes, facial flushing, night sweat, osteoporosis, fatigue, irritability, insomnia and / or sleep disorder, difficulty in concentration, depression, memory loss, brain fog, headache, migraine, anxiety, nervousness, restless, stress, mood swing, affect disorder, general discomfort, muscle tension, myalgia, intermittent dizziness, paresthesia, indigestion, digestive problems, intestinal disorders, abdominal pain, irritability, palpitations, tachycardia, nausea, constipation, diarrhea, arthralgia and / or arthritis, dysmenorrheal, pelvic pain, spasms, cramps, labor contraction, endometriosis Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia, premenstrual syndrome (PMS), premenstrual tension, premenstrual dysphoric disorder (PMDD), cold hands and feet, weight gain, mental awareness problems, sexual pain disorder, dyspareunia, breast pain and / or mastalgia, menopausal skin, inflammation, oxidative stress, cardiovascular disease, loss of pelvic muscle tone, urinary incontinence, lower urinary tract disorders, vaginal dryness, women urogenital and / or reproductive system infection, fibroid, myomas and / or cysts in the female genital system, human papillomavirus (HPV), Uterine Fibroid, cystitis, urethritis, pyelonephritis, women hormonal dysfunction and / or imbalance, irregular periods, pre-eclampsia toxemia, reduced libido, reduced sexual dysfunction, hair loss and / or thinning, age-related winkles, stretch marks, brittle nails, gam disorders, irregular body odor, conditions and / or symptoms induced by estrogen deficiency and combinations thereof.

[0013] According to an embodiment, the non-cannabinoid, non-terpene, carrier comprises cellulose, and the product comprises (a) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 5% by weight; (b) cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 5% by weight; (c) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 2.5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 2.5% by weight; or (d) at least one of cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and cannabicyclol (CBL), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), and non-decarboxylated form thereof in a concentration of at least 0.5% by weight; and (i) the primary terpene forms at least 40% by weight of the total terpene content, and (ii) the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1- ol, farensol, carotol, myrtenol and combinations thereof.

[0014] According to an embodiment, the product comprises (a) at least one cannabinoid from the group consisting of THC, CBD, CBG, CBC, CBN, CBL THCV, CBDV and their non- decarboxylated form thereof; (b) a non-cannabinoid, non-terpene carrier, comprising less than 5% by weight cellulose; (c) a primary terpene, forming at least 40% by weight of the total terpene content, wherein the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[0015] According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[0016] According to an embodiment, the product comprises less than 5% by weight glycol. According to an embodiment, the product comprises less than 20% by weight water. According to an embodiment, the product comprises chlorophyll. According to an embodiment, the product comprises at least one flavonoid. According to an embodiment, the product comprises at least one of isoflavones, coumestans, prenylflavonoids, lignans and saponins. According to an embodiment, the product comprises at least one of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin and cimicifugoside.

[0017] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect is at least 20% shorter than that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene.

[0018] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the magnitude of the therapeutic effect is at least 20% greater compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene.

[0019] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the duration of the therapeutic effect is at least 20% longer compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene.

[0020] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the frequency of the conditions and / or symptoms is at least 20% smaller compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene.

[0021] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the severity of the conditions and / or symptoms is at least 20% smaller compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene.

[0022] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the consumption of other drugs is reduced by at least 20% compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene.

[0023] According to an embodiment, the product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, the primary terpene is selected from the group consisting of caryophyllene, caryophyllene oxide, carene, eucalyptol, sabinene, pinene, limonene, borneol, thymol, camphor and combinations thereof, and the therapeutic effect treats osteoporosis. According to an embodiment, the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0024] According to an embodiment, the primary terpene is selected from the group consisting of linalool, caryophyllene, myrcene, terpineol, terpinene, citronellol, eucalyptol, nerolidol, sabinene, pinene, limonene, borneol, fenchol, bisabolol, humulene, phytol and combinations thereof, and the therapeutic effect treats sleep disorder and / or insomnia. According to an embodiment, the primary terpene includes terpineol, citronellol and / or linalool. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, chamazulene, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, the product comprises caryophyllene, and caryophyllene, forms less than 5% by weight of the total terpene content.

[0025] According to an embodiment, the product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, the primary terpene is selected from the group consisting of limonene, linalool, terpineol, citronellol, eucalyptol, caryophyllene, geraniol, menthol, iso-menthone, germacrene, pinene, citronellol, cardinol, neral, geranial, myrcene, terpinene, menth-2-en-l-ol, humulene, bisabolol, borneol, fenchol, nerolidol and combinations thereof, and the therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder. According to an embodiment, the primary terpene includes terpineol, citronellol and / or linalool. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, menthol, piperine, eugenol, citronellyl formate, jasmone, benzy acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, the product includes pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene, and pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene form less than 5% by weight of the total terpene content.

[0026] According to an embodiment, the product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, the primary terpene is selected from the group consisting of eucalyptol, pinene, carene, limonene, pulegone, terpineol, cymene, linalool, caryophyllene and combinations thereof, and the therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss. According to an embodiment, the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0027] According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool humulene, terpinene, borneol, caryophyllene and combinations thereof, and the therapeutic effect treats general discomfort. According to an embodiment, the product includes myrcene, pinene and / or bisabolol, and myrcene, pinene and / or bisabolol forms less than 5% by weight of the total terpene content.

[0028] According to an embodiment, the primary terpene is selected from the group consisting of myrcene, pinene, nerolidol, linalool, humulene, caryophyllene, limonene, bisabolol and combinations thereof, and the therapeutic effect treats muscle tension and / or myalgia.

[0029] According to an embodiment, the product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, the primary terpene is selected from the group consisting of pinene, limonene, terpinene, eucalyptol, myrcene, terpineol, linalool, caryophyllene and combinations thereof, and the therapeutic effect treats fatigue and / or intermittent dizziness.

[0030] According to an embodiment, the product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, the primary terpene is selected from the group consisting of linalool limonene, nerolidol, pinene terpineol, myrcene, geraniol, nerol, citronellol, farnesol, carotol and combinations thereof, and the therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, citronelly formate, eugenol, benzy acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0031] According to an embodiment, the primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, limonene, nerolidol, fenchol, humulene, guaiol, borneol, pinene, bisabolol, terpinene, terpineol and combinations thereof, and the therapeutic effect treats headache and / or migraine. According to an embodiment, the product includes bisabolol, terpinene, humulene and / or linalool and bisabolol, terpinene, humulene and / or linalool form less than 5% by weight of the total terpene content.

[0032] According to an embodiment, the product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, the primary terpene is selected from the group consisting of eucalyptol, caryophyllene, limonene, humulene, phytol and combinations thereof, and the therapeutic effect treats weight gain.

[0033] According to an embodiment, the primary terpene is selected from the group consisting of limonene, cymene, terpinene, caryophyllene, citronellol, sabinene, myrcene, linalool, germacrene, geraniol, pinene, terpineol and combinations thereof, and the therapeutic effect treats digestive problems, intestinal disorders, abdominal pain (colic), nausea, constipation and / or diarrhea. According to an embodiment, the product further comprises piperine. According to an embodiment, the product includes pinene, bisabolol, limonene and / or terpineol, and pinene, bisabolol, limonene and / or terpineol forms less than 5% by weight of the total terpene content.

[0034] According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, caryophyllene, myrcene, linalool, geraniol, eucalyptol, terpineol, sabinene and combinations thereof, and the therapeutic effect treats and breast pain and / or Mastalgia. According to an embodiment, the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0035] According to an embodiment, the primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, limonene, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso-menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2- en-l-ol and combinations thereof, and the therapeutic effect treats dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and / or endometriosis. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, methylis-oeugenol, menthol, eugenyl acetate, piperine, chamazulene, citronllyl formate, benzyl acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0036] According to an embodiment, the primary terpene is selected from the group consisting of myrcene, linalool, guaiol, caryophyllene, eucalyptol, pinene, nerolidol, sabinene, limonene, terpinene, menth-2-en-l-ol, geraniol, guaiol, humulene, bisabolol, borneol, fenchol, terpineol and combinations thereof, and the therapeutic effect treats arthralgia and / or arthritis. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, methylis-oeugenol, menthol, eugenyl acetate, piperine and combinations thereof. According to an embodiment, the product includes humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene, and humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene forms less than 5% by weight of the total terpene content.

[0037] According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene, myrcene, humulene, linalool, terpineol, geraniol, pinene, carene, citronellol, limonene, eucalyptol, sabinene, myrtenol, terpinene, champhene, borneol and combinations thereof, and the therapeutic effect treats hot flashes, facial flushing, night sweat, irritability, palpitation and / or tachycardia. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronellyl formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0038] According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene, pinene, myrcene, limonene, humulene, citronellol, eucalyptol, linalool, beta amyrin, cycloartenol, terpinene, terpineol, geraniol, carvacrol, thymol, cardinol, terpinene, menth-2-en-l-ol, carotol, humulene, nerolidol and combinations thereof, and the therapeutic effect treats inflammation, oxidative stress and / or paresthesia. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, eugenyl acetate, piperine and combinations thereof. According to an embodiment, the product includes caryophyllene and caryophyllene forms less than 5% by weight of the total terpene content.

[0039] According to an embodiment, the primary terpene is selected from the group consisting of linalool, camphene, limonene, pinene, borneol and combinations thereof, and the therapeutic effect treats cardiovascular disease, palpitation and tachycardia.

[0040] According to an embodiment, the primary terpene is selected from the group consisting of linalool, terpineol, pinene, carene, geraniol, thujone, camphor, viridiflorol, caryophyllene, germacrene, cirtonellol, eucalyptol, myrtenol, sanatalol, sabinene, limonene and combinations thereof, and the therapeutic effect treats urine incontinence and / or lower urinary tract disorders. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate and combinations thereof.

[0041] According to an embodiment, the primary terpene is selected from the group consisting of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l-ol, eucalyptol, myrtenol and combinations thereof, and the therapeutic effect treats vaginal dryness. According to an embodiment, the product further comprises a compound selected from the group consisting of linalyl acetate, geranyl acetate, citronellyl formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0042] According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, cymene, caryophyllene oxide, ocimene, nerolidol, eucalyptol, terpinene, terpineol, camphor, linalool, sabinene, thujone, camphor, viridiflorol, menthol, iso- menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, myrcene, menth-2-en-l-ol and combinations thereof, and the therapeutic effect treats female urogenital and / or reproductive system infection. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, eugenyl acetate, piperine, menthol, citronelly formate and combinations thereof. 11

[0043] According to an embodiment, the primary terpene is selected from the group consisting of linalool, terpineol, limonene, pinene, caryophyllene, caryophyllene oxide, terpinene, citronellol and combinations thereof, and the therapeutic effect treats fibroid, myomas and / or cysts in the female genital system.

[0044] According to an embodiment, the primary terpene is selected from the group consisting of thujone, pinene, limonene, cymene, caryophyllene, caryophyllene oxide, eucalyptol, terpineol, sabinene, linalool, cardinol and combinations thereof, and the therapeutic effect treats cystitis, urethritis and / or pyelonephritis. According to an embodiment, the product further comprises eugenol.

[0045] According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, terpineol, geraniol, eucalyptol, pinene, citronellol and combinations thereof, and the therapeutic effect treats reduced libido and / or sexual disfunction. According to an embodiment, the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0046] According to an embodiment, the primary terpene is selected from the group consisting of linalool, terpineol, eucalyptol, borneol, camphor, pinene, geraniol and combinations thereof, and the therapeutic effect treats hair loss and / or thinning.

[0047] According to an embodiment, the primary terpene is selected from the group consisting of linalool, eucalyptol, geraniol, pinene, limonene and combinations thereof, and the therapeutic effect treats brittle nails.

[0048] According to an embodiment, the primary terpene is selected from the group consisting of linalool, terpineol, geraniol, eucalyptol and combinations thereof, and the therapeutic effect treats irregular body odor.

[0049] According to an embodiment, the primary terpene is selected from the group consisting of humulene, linalool, terpineol, caryophyllene, caryophyllene oxide, terpinene, citronellol, geraniol, thujone, camphor, viridiflorol, pinene, camphene, sabinene, myrcene, eucalyptol, carene, carotol, limonene, sabinene, cardinal, pinene and combinations thereof, and the therapeutic effect treats Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, chamazulene, citronellyl formate and combinations thereof.

[0050] According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, eucalyptol, nerolidol, sabinene, pinene, caryophyllene, terpineol, geraniol, thujone, camphor, viridiflorol, champhene, myrcene, caryophyllene, terpinene, carene, cirtonellol, carotol, neral, geranial and combinations thereof, and the therapeutic effect treats premenstrual syndrome (PMS), premenstrual tension, and / or premenstrual dysphoric disorder (PMDD). According to an embodiment, the product further comprises a compound selected from the group consisting of linalyl acetate, geranyl acetate, citronellyl formate, menthol, eugenol piperine, jasmone and combinations thereof.

[0051] According to an embodiment, the primary terpene is selected from the group consisting of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2-en-l-ol, carotol, sabinene, neral, geranial and combinations thereof, and the therapeutic effect treats hormonal disfunction and / or imbalance and / or fertility. According to an embodiment, the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, chamazulene, citronelly formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, sclareol, diosgenin, acetin, cimicifugoside and combinations thereof.

[0052] According to an embodiment, the primary terpene is selected from the group consisting of limonene, neral, geranial, caryophyllene, linalool, myrcene, nerolidol, fenchol, humulene, guaiol, borneol, cymene, terpinene and combinations thereof, and the therapeutic effect treats pre-eclampsia toxemia.

[0053] According to an embodiment, the primary terpene is selected from the group consisting of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2-en-l-ol, carotol, sabinene, neral, geranial, nerolidol, terpineol, carene and combinations thereof, and the therapeutic effect treats conditions and / or symptoms associated with female hormonal disfunction and / or imbalance. According to an embodiment, the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0054] According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene, caryophyllene oxide, carene, linalool, myrcene, terpinene, terpineol, citronellol, eucalyptol, nerolidol, limonene, geraniol, menthol, iso-menthone, germacrene, pinene, cardinol, neral, geranial, menth-2-en-l-ol, pulegone, cymene, fenchol, humulene, guaiol, borneol, carene, sabinene, myrtenol, camphene, nerol, farnesol, carotol and combinationss thereof, and the therapeutic effect treats conditions and / or symptoms associated with perimenopause and / or menopause. According to an embodiment, the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0055] According to an embodiment, the primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso-menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2-en-l-ol, guaiol and combinations thereof, and the therapeutic effect treats pain and / or cramps.

[0056] According to an embodiment, the primary terpene is selected from the group consisting of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l-ol, borneol, eucalyptol, myrtenol, cymene, caryophyllene oxide, ocimene, nerolidol, camphor, sabinene, thujone, camphor, viridiflorol, menthol, iso-menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, thujone and combinations thereof, and the therapeutic effect treats female urogenital and / or reproductive system infections and / or disorders.

[0057] According to an embodiment, the product additionally contains an additive selected from the group consisting of antioxidants, emulsifiers and texturizers vegetable oils, plant extracts, honey, sucrose, glucose and fructose, pharmaceutical excipients and combinations thereof.

[0058] According to an embodiment, provided is a method for producing a product as disclosed herein, comprising providing at least one cannabinoid and blending it with a primary terpene. According to an embodiment, said method comprises contacting cannabis plant material with an extractant to form an extract, and said extract comprises at least one terpene. According to an embodiment, said method comprises synthesizing at least one cannabinoid and blending said synthesized cannabinoid with said primary terpene. According to an embodiment, said method comprises blending cannabis plant material with said primary. terpene.

[0059] According to an embodiment, provided is a method for achieving a therapeutic effect in treating conditions and / or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and / or disorders, menstrual cycle, hormonal deficiency and / or hormonal imbalance comprising administering to a subject in need a therapeutically effective amount of a product comprising (a) at least one cannabinoid in a specific amount, (b) a primary terpene in a specific amount, (c) at least 5% by weight of a non- cannabinoid, non-terpene carrier, (d) optionally at least three secondary terpenes, and (e) optionally at least one phytoestrogen, optionally combined with at least one herbal extract.

[0060] According to an embodiment, said product comprises less than 5% by weight glycol. According to an embodiment, said product comprises less than 20% by weight water. According to an embodiment, said product comprises chlorophyll. According to an embodiment, said product comprises at least one flavonoid. According to an embodiment, said product comprises at least one of isoflavones, coumestans, prenylflavonoids, lignans and saponins According to an embodiment, said product comprises at least one of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin and / or cimicifugoside.

[0061] According to an embodiment, said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in said product is about 0.1 to about 1.0. According to an embodiment, said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight / weight ratio in said product is about 0.05 to about 1.0.

[0062] According to an embodiment, said product additionally comprises an additive selected from the group consisting of antioxidants, emulsifiers and texturizers vegetable oils, plant extracts, honey, sucrose, glucose and fructose, pharmaceutical excipients and combinations thereof.

[0063] According to an embodiment, said conditions and / or symptoms are selected from the group consisting of hot flashes, facial flushing, night sweat, osteoporosis, fatigue, irritability, insomnia and / or sleep disorder, difficulty in concentration, depression, memory loss, brain fog, headache, migraine, anxiety, nervousness, restless, stress, mood swing, affect disorder, general discomfort, muscle tension, myalgia, intermittent dizziness, paresthesia, indigestion, digestive problems, intestinal disorders, abdominal pain, irritability, palpitations, tachycardia, nausea, constipation, diarrhea, arthralgia and / or arthritis, dysmenorrheal, pelvic pain, spasms, cramps, labor contraction, endometriosis Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia, premenstrual syndrome (PMS), premenstrual tension, premenstrual dysphoric disorder (PMDD), cold hands and feet, weight gain, mental awareness problems, sexual pain disorder, dyspareunia, breast pain and / or mastalgia, menopausal skin, inflammation, oxidative stress, cardiovascular disease, loss of pelvic muscle tone, urinary incontinence, lower urinary tract disorders, vaginal dryness, women urogenital and / or reproductive system infection, fibroid, myomas and / or cysts in the female genital system, human papillomavirus (HPV), Uterine Fibroid, cystitis, urethritis, pyelonephritis, women hormonal dysfunction and / or imbalance, irregular periods, pre-eclampsia toxemia, reduced libido, reduced sexual dysfunction, hair loss and / or thinning, age-related winkles, stretch marks, brittle nails, gam disorders, irregular body odor, conditions and / or symptoms induced by estrogen deficiency and combinations thereof.

[0064] According to an embodiment, said non-cannabinoid, non-terpene, carrier comprises cellulose, and said product comprises: (i) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 5% by weight; (ii) cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 5% by weight; (iii) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 2.5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a concentration of at least 2.5% by weight; and / or at least one of cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and Cannabicyclol (CBL), tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV), and non-decarboxylated form thereof in a concentration of at least 0.5% by weight; and (a) said primary terpene forms at least 40% by weight of the total terpene content, and (b) said primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[0065] According to an embodiment, (i) said at least one cannabinoid is selected from the group consisting of THC, CBD, CBG, CBC, CBN, CBL, THCV, CBDV and non-decarboxylated form thereof; (ii) the non-cannabinoid, non-terpene, carrier comprises less than 5% by weight cellulose; (iii) said primary terpene forms at least 40% by weight of the total terpene content, and (iv) said primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[0066] According to an embodiment, said primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[0067] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the onset time of said therapeutic effect is at least 20% shorter than that of administering a product comprising the same cannabinoids amounts and one half the amount of said primary terpene. According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the magnitude of the therapeutic effect is at least 20% greater compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of said primary terpene. According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the duration of the therapeutic effect is at least 20% longer compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of said primary terpene. According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the frequency of said conditions and / or symptoms is at least 20% smaller compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of said primary terpene. According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the severity of said conditions and / or symptoms is at least 20% smaller compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of said primary terpene. According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the consumption of other drugs is reduced by at least 20% compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of said primary terpene.

[0068] According to an embodiment, said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, said primary terpene is selected from the group consisting of caryophyllene, caryophyllene oxide, carene, eucalyptol, sabinene, pinene, limonene, borneol, thymol, camphor and combinations thereof, and said therapeutic effect treats osteoporosis. According to an embodiment, said product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, said product further comprises a herbal extract selected from the group consisting of extracts of angelica sinensis, cimicifuga (Actaea) racemosa, dioscorea villosa, trifolium pratense and combinations thereof.

[0069] According to an embodiment, said primary terpene is selected from the group consisting of linalool, caryophyllene, myrcene, terpineol, terpinene, citronellol, eucalyptol, nerolidol, sabinene, pinene, limonene, borneol, fenchol, bisabolol humulene, phytol and combinations thereof, and said therapeutic effect treats sleep disorder and / or insomnia. According to a related embodiment, said primary terpene includes terpineol, citronellol and / or linalool. According to an embodiment, said product further comprises a compound selected from the group consisting of linally acetate, chamazulene, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product further comprises a herbal extract selected from the group consisting of extracts of avena sativa, cimicifuga (actaea) racemosa, humulus lupulus, hypericum perforatum, lavendula officinalis, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof. According to a related embodiment, said product comprises caryophyllene, and caryophyllene, forms less than 5% by weight of the total terpene content.

[0070] According to an embodiment, said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, said primary terpene is selected from the group consisting of limonene, linalool, terpineol, citronellol, eucalyptol, caryophyllene, geraniol, menthol, iso-menthone, germacrene, pinene, citronellol, cardinol, neral, geranial, myrcene, terpinene, menth-2-en-l-ol, humulene, bisabolol, borneol, fenchol, nerolidol and combinations thereof, and said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder. According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, geranyl acetate, menthol, piperine, eugenol, citronellyl formate, jasmone, benzy acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of avena sativa, bacopa monnieri, centella (Hydrocotyl) asiatica, humulus lupulus, hypericum perforatum, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof. According to a related embodiment, said product comprises pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene, and pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene forms less than 5% by weight of the total terpene content.

[0071] According to an embodiment, said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, said primary terpene is selected from the group consisting of eucalyptol, pinene, carene, limonene, pulegone, terpineol, cymene, linalool, caryophyllene and combinations thereof, and said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss. According to a related embodiment, said product comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of asphalentum ponjabianum - mumio, bacopa monnieri, centella (hydrocotyl) asiatica, eleutherococcus senticosus, ginkgo biloba, lepidium meyenii, lycium barbarum, paullinia cupana, rhodiola rosea and combinations thereof.

[0072] According to an embodiment, primary terpene is selected from the group consisting of limonene, linalool, humulene, terpinene, borneol, caryophyllene and combinations thereof, and said therapeutic effect treats general discomfort. According to a related embodiment, said product comprises myrcene, pinene and / or bisabolol, and myrcene, pinene and / or bisabolol forms less than 5% by weight of the total terpene content.

[0073] According to an embodiment, said primary terpene is selected from the group consisting of myrcene, pinene, nerolidol, linalool, humulene, caryophyllene, limonene, bisabolol and combinations thereof, and said therapeutic effect treats muscle tension and / or myalgia. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of boswellia spp, salix alba, valeriana edulis, viburnum opulus, chamaemelum and combinations thereof.

[0074] According to an embodiment, said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, said primary terpene is selected from the group consisting of pinene, limonene, terpinene, eucalyptol, myrcene, terpineol, linalool, caryophyllene and combinations thereof, and said therapeutic effect treats fatigue and / or intermittent dizziness. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of eleutherococcus senticosus, ganoderma lucidum, grifola frondosa, lentinula edodes, lepidium meyenii, panax ginseng, rhodiola rosea and combinations thereof.

[0075] According to an embodiment, said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, said primary terpene is selected from the group consisting of linalool limonene, nerolidol, pinene terpineol, myrcene, geraniol, nerol, citronellol, farnesol, carotol and combinations thereof, and said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks. According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, citronelly formate, eugenol, benzy acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of glycyrrhiza glabra, plantago spp, symphytum officinalis, trifolium pratense, trigonella foenum graecum, ulmus rubra\fulva, verbascum thapsus and combinations thereof.

[0076] According to an embodiment, said primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, limonene, nerolidol, fenchol, humulene, guaiol, borneol, pinene, bisabolol, terpinene, terpineol and combinations thereof, and said therapeutic effect treats headache and / or migraine. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of angelica sinensis, corydalis yanhusuo, piscidia erythrina, rosmarinus officinalis, stachys betonica, tanacetum parthenium, verbena officinalis and combinations thereof. According to a related embodiment, said product comprises bisabolol, terpinene, humulene and / or linalool and bisabolol, terpinene, humulene and / or linalool forms less than 5% by weight of the total terpene content.

[0077] According to an embodiment, said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, said primary terpene is selected from the group consisting of eucalyptol, caryophyllene, limonene, humulene, phytol and combinations thereof, and said therapeutic effect treats weight gain. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of ephedra sinica, foeniculum vulgare, fucus vesiculosus, garcinia cambogia, gymnema sylvestre, laminaria spp, paullinia cupana and combinations thereof.

[0078] According to an embodiment, said primary terpene is selected from the group consisting of limonene, cymene, terpinene, caryophyllene, citronellol, sabinene, myrcene, linalool, germacrene, geraniol, pinene, terpineol and combinations thereof, and said therapeutic effect treats digestive problems, intestinal disorders, abdominal pain (colic), nausea, constipation and / or diarrhea. According to a related embodiment, said product comprises piperine. According to a related embodiment, said product comprises pinene, bisabolol, limonene and / or terpineol, and pinene, bisabolol, limonene and / or terpineol forms less than 5% by weight of the total terpene content.

[0079] According to an embodiment, said primary terpene is selected from the group consisting of pinene, limonene, caryophyllene, myrcene, linalool, geraniol, eucalyptol, terpineol, sabinene and combinations thereof, and said therapeutic effect treats breast pain and / or Mastalgia. According to a related embodiment, said product comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[0080] According to an embodiment, said primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, limonene, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso-menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2- en-l-ol and combinations thereof, and said therapeutic effect treats dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and / or endometriosis. According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, methylis-oeugenol, menthol, eugenyl acetate, piperine, chamazulene, citronllyl formate, benzyl acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of cimicifuga (actaea) racemosa, paeonia lactiflora, viburnum opulus, viburnum opulus, vitex agnus castus and combinations thereof.

[0081] According to an embodiment, said primary terpene is selected from the group consisting of myrcene, linalool, guaiol, caryophyllene, eucalyptol, pinene, nerolidol, sabinene, limonene, terpinene, menth-2-en-l-ol, geraniol, guaiol, humulene, bisabolol, borneol, fenchol, terpineol and combinations thereof, and said therapeutic effect treats arthralgia and / or arthritis. According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, methylis-oeugenol, menthol, eugenyl acetate, piperine and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of boswellia spp, capsicum spp, corydalis yanhusuo, harpagophytum procumbens, piscidia erythrina, salix alba, zingiber officinalis and combinations thereof. According to a related embodiment, said product comprises humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene, and humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene forms less than 5% by weight of the total terpene content.

[0082] According to an embodiment, said primary terpene is selected from the group consisting of caryophyllene, myrcene, humulene, linalool, terpineol, geraniol, pinene, carene, citronellol, limonene, eucalyptol, sabinene, myrtenol, terpinene, champhene, borneol and combinations thereof, and said therapeutic effect treats hot flashes, facial flushing, night sweat, irritability, palpitation and / or tachycardia. According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronellyl formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of angelica sinensis, anemarrhenae asphodeloides, cimicifuga (actaea) racemosa, dioscorea villosa, salvia officinalis, salvia officinalis, rehmania glutinosa preparata and combinations thereof.

[0083] According to an embodiment, said primary terpene is selected from the group consisting of caryophyllene, pinene, myrcene, limonene, humulene, citronellol, eucalyptol, linalool, beta amyrin, cycloartenol, terpinene, terpineol, geraniol, carvacrol, thymol, cardinol, terpinene, menth-2-en-l-ol, carotol, humulene, nerolidol and combinations thereof, and said therapeutic effect treats inflammation, oxidative stress and / or paresthesia. According to a related embodiment, said composition comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, eugenyl acetate, piperine and combinations thereof. According to a related embodiment, said product comprises caryophyllene and caryophyllene forms less than 5% by weight of the total terpene content.

[0084] According to an embodiment, said primary terpene is selected from the group consisting of linalool, camphene, limonene, pinene, borneol and combinations thereof, and said therapeutic effect treats cardiovascular disease, palpitation and tachycardia. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of cimicifuga (actaea) racemosa, crataegus spp, leonurus spp, passiflora incarnata and combinations thereof.

[0085] According to an embodiment, said primary terpene is selected from the group consisting of linalool, terpineol, pinene, carene, geraniol, thujone, camphor, viridiflorol, caryophyllene, germacrene, cirtonellol, eucalyptol, myrtenol, sanatalol, sabinene, limonene and combinations thereof, and said therapeutic effect treats urine incontinence and / or lower urinary tract disorders. According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of barosma betulina, equisitum arvense, plantago spp, urtica dioicanettle and combinations thereof.

[0086] According to an embodiment, said primary terpene is selected from the group consisting of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l-ol, eucalyptol, myrtenol and combinations thereof, and said therapeutic effect treats vaginal dryness. According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronellyl formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of dioscorea villosa spp, vitex agnus castus, withania somnifera, schisandra chinensis and combinations thereof.

[0087] According to an embodiment, said primary terpene is selected from the group consisting of pinene, limonene, cymene, caryophyllene oxide, ocimene, nerolidol, eucalyptol, terpinene, terpineol, camphor, linalool, sabinene, thujone, camphor, viridiflorol, menthol, iso- menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, myrcene, menth-2-en-l-ol and combinations thereof, and said therapeutic effect treats female urogenital and / or reproductive system infections. According to a related embodiment, said product comprises a compound selected from the group consisting of linalyl acetate, geranyl acetate, eugenol, eugenyl acetate, piperine, menthol, citronellyl formate and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of anemarrhenae asphodeloides, cimicifuga (actaea) racemosa, coptis chinensis, echinacea spp, hydrastis canadensis and combinations thereof.

[0088] According to an embodiment, said primary terpene is selected from the group consisting of linalool, terpineol, limonene, pinene, caryophyllene, caryophyllene oxide, terpinene, citronellol and combinations thereof, and said therapeutic effect treats fibroid, myomas and / or cysts in the female genital system. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of angellica sinesis, larrea mexicana, viburnum prunifolium, vitex agnus castus, trifolium and combinations thereof.

[0089] According to an embodiment, said primary terpene is selected from the group consisting of thujone, pinene, limonene, cymene, caryophyllene, caryophyllene oxide, eucalyptol, terpineol, sabinene, linalool, cardinol and combinations thereof, and said therapeutic effect treats cystitis, urethritis and / or pyelonephritis. According to a related embodiment, said product comprises comprising eugenol. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of althea officinalis, andrographis paniculata, anemarrhenae asphodeloides, apium graveolens, arctostaphylos uva-ursi, barosma betulina, coptis chinensis, echinacea spp, hydrastis canadensis, plantago spp, uncaria tomentosa, zea mays and combinations thereof.

[0090] According to an embodiment, said primary terpene is selected from the group consisting of limonene, linalool, terpineol, geraniol, eucalyptol, pinene, citronellol and combinations thereof, and said therapeutic effect treats reduced libido and / or sexual disfunction. According to a related embodiment, said product comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of epimedium grandiflorum, ganoderma lucidum, lepidium meyenii, turnera diffusa, vitex agnus castus, withania somnifera and combinations thereof.

[0091] According to an embodiment, said primary terpene is selected from the group consisting of linalool, terpineol, eucalyptol, borneol, camphor, pinene, geraniol and combinations thereof, and said therapeutic effect treats hair loss and / or thinning. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of rehmania glutinosa preparata, rosmarinus officinalis, serenoa serrulata, urtica dioica and combinations thereof.

[0092] According to an embodiment, said primary terpene is selected from the group consisting of linalool, eucalyptol, pinene, limonene and combinations thereof, and said therapeutic effect treats brittle nails.

[0093] According to an embodiment, said primary terpene is selected from the group consisting of linabool, terpineol and combinations thereof, and said therapeutic effect treats irregular body odor.

[0094] According to an embodiment, said primary terpene is selected from the group consisting of humulene, linalool, terpineol, caryophyllene, caryophyllene oxide, terpinene, citronellol, geraniol, thujone, camphor, viridiflorol, pinene, camphene, sabinene, myrcene, eucalyptol, carene, carotol, limonene, sabinene, cardinal, pinene and combinations thereof, and said therapeutic effect treats Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia. According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, chamazulene, citronellyl formate and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of angelica sinensis, cimicifuga (actaea) racemosa, dioscorea villosa spp., vitex agnus castus, humulus lupulus, hypericum perforatum, lavendula officinalis, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof.

[0095] According to an embodiment, said primary terpene is selected from the group consisting of limonene, linalool, eucalyptol, nerolidol, sabinene, pinene, caryophyllene, terpineol, geraniol, thujone, camphor, viridiflorol, champhene, myrcene, caryophyllene, terpinene, carene, cirtonellol, carotol, neral, geranial and combinations thereof, and said therapeutic effect treats premenstrual syndrome (PMS), premenstrual tension, and / or premenstrual dysphoric disorder (PMDD). According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate, menthol, eugenol piperine, jasmone and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of angelica sinensis, cimicifuga (actaea) racemosa, dioscorea villosa spp, paeonia lactiflora, vitex agnus castus and combinations thereof.

[0096] According to an embodiment, said primary terpene is selected from the group consisting of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2-en-l-ol, carotol, sabinene, neral, geranial and combinations thereof, and said therapeutic effect treats hormonal disfunction and / or imbalance and / or fertility. According to a related embodiment, said product comprises a compound selected from the group consisting of linally acetate, geranyl acetate, chamazulene, citronelly formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, sclareol, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of angelica sinensis, cimicifuga (actaea) racemosa, dioscorea villosa spp, trifolium pratense, vitex agnus castus and combinations thereof.

[0097] According to an embodiment, said primary terpene is selected from the group consisting of limonene, neral, geranial, caryophyllene, linalool, myrcene, nerolidol, fenchol, humulene, guaiol, borneol, cymene, terpinene and combinations thereof, and said therapeutic effect treats pre-eclampsia toxemia. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of Crataegus spp, olea europea, passiflora incarnata and combinations thereof.

[0098] According to an embodiment, said primary terpene is selected from the group consisting of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2-en-l-ol, carotol, sabinene, neral, geranial, nerolidol, terpineol, carene and combinations thereof, and said therapeutic effect treats conditions and / or symptoms associated with female hormonal disfunction and / or imbalance. According to a related embodiment, said product comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of angelica sinensis, chamaelirium lutea, cimicifuga (actaea) racemosa, dioscorea villosa spp., trifolium pratense, vitex agnus castus and combinations thereof.

[0099] According to an embodiment, said primary terpene is selected from the group consisting of caryophyllene, caryophyllene oxide, carene, linalool, myrcene, terpinene, terpineol, citronellol, eucalyptol, nerolidol, limonene, geraniol, menthol, iso-menthone, germacrene, pinene, cardinol, neral, geranial, menth-2-en-l-ol, pulegone, cymene, fenchol, humulene, guaiol, borneol, carene, sabinene, myrtenol, camphene, nerol, farnesol, carotol and combinations thereof, and said therapeutic effect treats conditions and / or symptoms associated with perimenopause and / or menopause. According to a related embodiment, said product comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of angelica sinensis, anemarrhenae asphodeloides, cimicifuga (actaea) racemosa, glycyrrhiza glabra. hypericum perforatum, panax quinquefolium, trifolium pratense, avena sativa, cimicifuga (actaea) racemosa, humulus lupulus, hypericum perforatum, lavendula officinalis, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof.

[00100] According to an embodiment, said primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso-menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2-en-l-ol, guaiol and combinations thereof, and said therapeutic effect treats pain and / or cramps. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of angelica sinensis, piscidia erythrina, tanacetum parthenium, viburnum opulus, boswellia spp, capsicum spp, corydalis yanhusuo, harpagophytum procumbens, rosmarinus officinalis, salix alba, zingiber officinalis and combinations thereof.

[00101] According to an embodiment, said primary terpene is selected from the group consisting of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l-ol, borneol, eucalyptol, myrtenol, cymene, caryophyllene oxide, ocimene, nerolidol, camphor, sabinene, thujone, camphor, viridiflorol, menthol, iso-menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, thujone and combinations thereof, and said therapeutic effect treats female urogenital and / or reproductive system infections and / or disorders. According to a related embodiment, said product comprises a herbal extract selected from the group consisting of extracts of apium graveolens, dioscorea villosa spp, althea officinalis, anemarrhenae asphodeloides, anemarrhenae asphodeloides, apium graveolens, arctostaphylos uva—ursi, barosma betulina, coptis chinensis, echinacea spp, equisitum arvense, hydrastis canadensis, plantago spp, serenoa serrulata, uncaria tomentosa, urtica dioica, viola tricolor, zea mays and combinations thereof.

[00102] According to an embodiment said terpene-enriched cannabinoid product is produced by adding isolated terpenes to a cannabis extract.

[00103] According to an embodiment said method comprises administering to said subject for a first period of time a first said product comprising a first cannabinoid at a first cannabinoid amount and a first primary terpene at a first primary terpene amount, followed by (i) administering to said subject for a second period of time said product comprising said first cannabinoid at said first cannabinoid amount or less and a second primary terpene at a second primary terpene amount; (ii) administering to said subject for a second period of time said product comprising said first cannabinoid at said first cannabinoid amount or less and a first primary terpene at an increased first primary terpene amount; (iii) administering to said subject for a second period of time said product comprising said first cannabinoid at a said first cannabinoid amount or less, first primary terpene at a first primary terpene amount and at least one secondary terpene; and / or (iv) administering to said subject for a second period of time said product comprising said first cannabinoid at a said first cannabinoid amount or less, first primary terpene at a first primary terpene amount and a second primary terpene.

[00104] According to an embodiment said method comprises administering to said subject a product selected from the group consisting of tablets, gel capsules, medical patches, topicals, creams, varnishes, sublingual oils, sprays, edibles, suppositories, tampons, rectal candles, cigarettes, vaporizer liquids, nasal preparartions, preparations containing micro and / or nano- emulsions, preparations containing micro and / or nano-particles and combinations thereof.

[00105] According to an embodiment, further provided is a method for achieving, reaching and / or gaining a therapeutic effect in treating conditions and / or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and / or disorders, menstrual cycle, hormonal deficiency and / or hormonal imbalance comprising administering to a subject in need a therapeutically effective amount of a composition comprising (i) a primary terpene in a specific amount; (ii) optionally at least three secondary terpenes; (iii) optionally at least one cannabinoid in a specific amount; and (iv) optionally at least one phytoestrogen. According to an embodiment, the composition comprises at least 5% by weight of a non-cannabinoid, non-terpene carrier.

[00106] According to an embodiment, the conditions and / or symptoms are selected from the group consisting of hot flashes, facial flushing, night sweat, osteoporosis, fatigue, irritability, insomnia and / or sleep disorder, difficulty in concentration, depression, memory loss, brain fog, headache, migraine, anxiety, nervousness, restless, stress, mood swing, affect disorder, general discomfort, muscle tension, myalgia, intermittent dizziness, paresthesia, indigestion, digestive problems, intestinal disorders, abdominal pain, irritability, palpitations, tachycardia, nausea, constipation, diarrhea, arthralgia and / or arthritis, dysmenorrheal, pelvic pain, spasms, cramps, labor contraction, endometriosis Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia, premenstrual syndrome (PMS), premenstrual tension, premenstrual dysphoric disorder (PMDD), cold hands and feet, weight gain, mental awareness problems, sexual pain disorder, dyspareunia, breast pain and / or mastalgia, menopausal skin, inflammation, oxidative stress, cardiovascular disease, loss of pelvic muscle tone, urinary incontinence, lower urinary tract disorders, vaginal dryness, women urogenital and / or reproductive system infection, fibroid, myomas and / or cysts in the female genital system, human papillomavirus (HPV), Uterine Fibroid, cystitis, urethritis, pyelonephritis, women hormonal dysfunction and / or imbalance, irregular periods, pre-eclampsia toxemia, reduced libido, reduced sexual dysfunction, hair loss and / or thinning, age-related winkles, stretch marks, brittle nails, gam disorders, irregular body odor, conditions and / or symptoms induced by estrogen deficiency and combinations thereof.

[00107] According to an embodiment, the composition additionally contains an additive selected from the group consisting of antioxidants, emulsifiers and texturizers vegetable oils, plant extracts, honey, sucrose, glucose and fructose, pharmaceutical excipients and combinations thereof.

[00108] According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[00109] According to an embodiment, the composition comprises at least one of isoflavones, coumestans, prenylflavonoids, lignans and saponins. According to an embodiment, the composition comprises at least one of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin and cimicifugoside.

[00110] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect is at least 20% shorter than that of a composition comprising one half the amount of the primary terpene.

[00111] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the magnitude of the therapeutic effect is at least 20% greater compared with that of a composition comprising one half the amount of the primary terpene.

[00112] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the duration of the therapeutic effect is at least 20% longer compared with that of a composition comprising one half the amount of the primary terpene.

[00113] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the frequency of the conditions and / or symptoms is at least 20% smaller compared with that of a composition one half the amount of the primary terpene.

[00114] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the severity of the conditions and / or symptoms is at least 20% smaller compared with that of a composition comprising one half the amount of the primary terpene.

[00115] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the consumption of other drugs is reduced by at least 20% compared with that of a composition comprising one half the amount of the primary terpene.

[00116] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of caryophyllene, caryophyllene oxide, carene, eucalyptol, sabinene, pinene, limonene, borneol, thymol, camphor, and the therapeutic effect treats osteoporosis. According to an embodiment, the composition further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00117] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of linalool, caryophyllene, myrcene, terpineol, terpinene, citronellol, eucalyptol, nerolidol, sabinene, pinene, limonene, borneol, fenchol, bisabolol, humulene, phytol, and the therapeutic effect treats sleep disorder and / or insomnia. According to an embodiment, the primary terpene includes terpineol, citronellol and / or linalool. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, chamazulene, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, the composition comprises caryophyllene, wherein caryophyllene, forms less than 5% by weight of the total terpene content.

[00118] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of limonene, linalool, terpineol, citronellol, eucalyptol, caryophyllene, geraniol, menthol, iso-menthone, germacrene, pinene, citronellol, cardinol, neral, geranial, myrcene, terpinene, menth-2-en-l-ol, humulene, bisabolol, borneol, fenchol, nerolidol and the therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder. According to an embodiment, the primary terpene includes terpineol, citronellol and / or linalool. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, menthol, piperine, eugenol, citronellyl formate, jasmone, benzy acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, the composition includes pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene, and pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene form less than 5% by weight of the total terpene content.

[00119] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of eucalyptol, pinene, carene, limonene, pulegone, terpineol, cymene, linalool, caryophyllene and the therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss. According to an embodiment, the composition further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00120] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of limonene, linalool humulene, terpinene, borneol, caryophyllene, and the therapeutic effect treats general discomfort. According to an embodiment, the composition includes myrcene, pinene and / or bisabolol, and myrcene, pinene and / or bisabolol forms less than 5% by weight of the total terpene content.

[00121] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of myrcene, pinene, nerolidol, linalool, humulene, caryophyllene, limonene, bisabolol, and the therapeutic effect treats muscle tension and / or myalgia.

[00122] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of pinene, limonene, terpinene, eucalyptol, myrcene, terpineol, linalool, caryophyllene, and the therapeutic effect treats fatigue and / or intermittent dizziness.

[00123] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of linalool limonene, nerolidol, pinene terpineol, myrcene, geraniol, nerol, citronellol, farnesol, carotol, and the therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, citronelly formate, eugenol, benzy acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00124] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of myrcene, linalool, caryophyllene, eucalyptol, limonene, nerolidol, fenchol, humulene, guaiol, borneol, pinene, bisabolol, terpinene, terpineol and the therapeutic effect treats headache and / or migraine. According to an embodiment, the composition includes bisabolol, terpinene, humulene and / or linalool and bisabolol, terpinene, humulene and / or linalool form less than 5% by weight of the total terpene content.

[00125] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or all five of eucalyptol, caryophyllene, limonene, humulene, phytol, and the therapeutic effect treats weight gain.

[00126] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of limonene, cymene, terpinene, caryophyllene, citronellol, sabinene, myrcene, linalool, germacrene, geraniol, pinene, terpineol and the therapeutic effect treats digestive problems, intestinal disorders, abdominal pain (colic), nausea, constipation and / or diarrhea. According to an embodiment, the composition further comprises piperine. According to an embodiment, the composition includes pinene, bisabolol, limonene and / or terpineol, wherein pinene, bisabolol, limonene and / or terpineol forms less than 5% by weight of the total terpene content.

[00127] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of pinene, limonene, caryophyllene, myrcene, linalool, geraniol, eucalyptol, terpineol, sabinene, and the therapeutic effect treats and breast pain and / or Mastalgia. According to an embodiment, the composition further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00128] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, limonene, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso- menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2-en-l-ol, and the therapeutic effect treats dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and / or endometriosis. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, methylis-oeugenol, menthol, eugenyl acetate, piperine, chamazulene, citronllyl formate, benzyl acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00129] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of myrcene, linalool, guaiol, caryophyllene, eucalyptol, pinene, nerolidol, sabinene, limonene, terpinene, menth-2-en-l-ol, geraniol, guaiol, humulene, bisabolol, borneol, fenchol, terpineol, and the therapeutic effect treats arthralgia and / or arthritis. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, methylis- oeugenol, menthol, eugenyl acetate, piperine and combinations thereof. According to an embodiment, the composition includes humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene, wherein humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene forms less than 5% by weight of the total terpene content.

[00130] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of caryophyllene, myrcene, humulene, linalool, terpineol, geraniol, pinene, carene, citronellol, limonene, eucalyptol, sabinene, myrtenol, terpinene, champhene, borneol and the therapeutic effect treats hot flashes, facial flushing, night sweat, irritability, palpitation and / or tachycardia. According to an embodiment, the composition further comprises a compound selected from the group consisting of linalyl acetate, geranyl acetate, citronellyl formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00131] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of caryophyllene, pinene, myrcene, limonene, humulene, citronellol, eucalyptol, linalool, beta amyrin, cycloartenol, terpinene, terpineol, geraniol, carvacrol, thymol, cardinol, terpinene, menth-2-en-l-ol, carotol, humulene, nerolidol and the therapeutic effect treats inflammation, oxidative stress and / or paresthesia. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, eugenyl acetate, piperine and combinations thereof. According to an embodiment, the composition includes caryophyllene and caryophyllene forms less than 5% by weight of the total terpene content.

[00132] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or all five of linalool, camphene, limonene, pinene, borneol, and the therapeutic effect treats cardiovascular disease, palpitation and tachycardia.

[00133] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of linalool, terpineol, pinene, carene, geraniol, thujone, camphor, viridiflorol, caryophyllene, germacrene, cirtonellol, eucalyptol, myrtenol, sanatalol, sabinene, limonene, and the therapeutic effect treats urine incontinence and / or lower urinary tract disorders. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronellyl formate and combinations thereof.

[00134] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l-ol, eucalyptol, myrtenol, and the therapeutic effect treats vaginal dryness. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00135] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of pinene, limonene, cymene, caryophyllene oxide, ocimene, nerolidol, eucalyptol, terpinene, terpineol, camphor, linalool, sabinene, thujone, camphor, viridiflorol, menthol, iso-menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, myrcene, menth-2-en-l-ol, and the therapeutic effect treats female urogenital and / or reproductive system infection. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, eugenyl acetate, piperine, menthol, citronelly formate and combinations thereof.

[00136] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of linalool, terpineol, limonene, pinene, caryophyllene, caryophyllene oxide, terpinene, citronellol, and the therapeutic effect treats fibroid, myomas and / or cysts in the female genital system.

[00137] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of thujone, pinene, limonene, cymene, caryophyllene, caryophyllene oxide, eucalyptol, terpineol, sabinene, linalool, cardinol, and the therapeutic effect treats cystitis, urethritis and / or pyelonephritis. According to an embodiment, the composition further comprises eugenol.

[00138] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of limonene, linalool, terpineol, geraniol, eucalyptol, pinene, citronellol, and the therapeutic effect treats reduced libido and / or sexual disfunction. According to an embodiment, the composition further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00139] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of linalool, terpineol, eucalyptol, borneol, camphor, pinene, geraniol, and the therapeutic effect treats hair loss and / or thinning.

[00140] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or all five of linalool, eucalyptol, geraniol, pinene, limonene, and the therapeutic effect treats brittle nails.

[00141] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, or all four of linalool, terpineol, geraniol, eucalyptol, and the therapeutic effect treats irregular body odor.

[00142] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of humulene, linalool, terpineol, caryophyllene, caryophyllene oxide, terpinene, citronellol, geraniol, thujone, camphor, viridiflorol, pinene, camphene, sabinene, myrcene, eucalyptol, carene, carotol, limonene, sabinene, cardinal, pinene, and the therapeutic effect treats Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, chamazulene, citronellyl formate and combinations thereof.

[00143] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of limonene, linalool, eucalyptol, nerolidol, sabinene, pinene, caryophyllene, terpineol, geraniol, thujone, camphor, viridiflorol, champhene, myrcene, caryophyllene, terpinene, carene, cirtonellol, carotol, neral, geranial, and the therapeutic effect treats premenstrual syndrome (PMS), premenstrual tension, and / or premenstrual dysphoric disorder (PMDD). According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate, menthol, eugenol piperine, jasmone and combinations thereof.

[00144] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2- en-l-ol, carotol, sabinene, neral, geranial, and the therapeutic effect treats hormonal disfunction and / or imbalance and / or fertility. According to an embodiment, the composition further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, chamazulene, citronellyl formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, sclareol, diosgenin, acetin, cimicifugoside and combinations thereof.

[00145] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of limonene, neral, geranial, caryophyllene, linalool, myrcene, nerolidol, fenchol, humulene, guaiol, borneol, cymene, terpinene, and the therapeutic effect treats pre-eclampsia toxemia.

[00146] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2- en-l-ol, carotol, sabinene, neral, geranial, nerolidol, terpineol, carene, and the therapeutic effect treats conditions and / or symptoms associated with female hormonal disfunction and / or imbalance. According to an embodiment, the composition further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00147] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of caryophyllene, caryophyllene oxide, carene, linalool, myrcene, terpinene, terpineol, citronellol, eucalyptol, nerolidol, limonene, geraniol, menthol, iso-menthone, germacrene, pinene, cardinol, neral, geranial, menth-2-en-l-ol, pulegone, cymene, fenchol, humulene, guaiol, borneol, carene, sabinene, myrtenol, camphene, nerol, farnesol, carotol, and the therapeutic effect treats conditions and / or symptoms associated with perimenopause and / or menopause. According to an embodiment, the composition further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00148] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso-menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2-en-l-ol, guaiol, and the therapeutic effect treats pain and / or cramps.

[00149] According to an embodiment, the primary terpene is selected from the group consisting of at least two, at least three, at least four or at least five of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l-ol, borneol, eucalyptol, myrtenol, cymene, caryophyllene oxide, ocimene, nerolidol, camphor, sabinene, thujone, camphor, viridiflorol, menthol, iso-menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, thujone, and the therapeutic effect treats female urogenital and / or reproductive system infections and / or disorders.

[00150] According to an embodiment, provided is a method for treating women health comprising administering to the subject a product selected from the group consisting of tablets, gel capsules, medical patches, topicals, creams, varnishes, sublingual oils, sprays, edibles, suppositories, tampons, rectal candles, cigarettes, vaporizer liquids, nasal preparartions, preparations containing micro and / or nano-emulsions, preparations containing micro and / or nano-particles and combinations thereof.

[00151] According to an embodiment, provided is a composition comprising five or less terpenes in a concentration of at least 10% of the total terpene content, forming a terpene composition with enhanced therapeutic effect for treating conditions and / or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and / or disorders, menstrual cycle, hormonal deficiency and / or hormonal imbalance.

[00152] According to an embodiment, the composition comprises at least one of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[00153] According to an embodiment, the conditions and / or symptoms are selected from the group consisting of conditions and / or symptoms induced by estrogen deficiency, hot flashes, facial flushing, night sweat, osteoporosis, fatigue, irritability, insomnia and / or sleep disorder, difficulty in concentration, depression, memory loss, brain fog, headache, migraine, anxiety, nervousness, restless, stress, mood swing, affect disorder, general discomfort, muscle tension, myalgia, intermittent dizziness, paresthesia, indigestion, digestive problems, intestinal disorders, abdominal pain, irritability, palpitations, tachycardia, nausea, constipation, diarrhea, arthralgia and / or arthritis, dysmenorrheal, pelvic pain, spasms, cramps, labor contraction, endometriosis Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia, premenstrual syndrome (PMS), premenstrual tension, premenstrual dysphoric disorder (PMDD), cold hands and feet, weight gain, mental awareness problems, sexual pain disorder, dyspareunia, breast pain and / or mastalgia, menopausal skin, inflammation, oxidative stress, cardiovascular disease, loss of pelvic muscle tone, urinary incontinence, lower urinary tract disorders, vaginal dryness, women urogenital and / or reproductive system infection, fibroid, myomas and / or cysts in the female genital system, human papillomavirus (HPV), Uterine Fibroid, cystitis, urethritis, pyelonephritis, women hormonal dysfunction and / or imbalance, irregular periods, pre-eclampsia toxemia, reduced libido, reduced sexual dysfunction, hair loss and / or thinning, age-related winkles, stretch marks, brittle nails, gam disorders, irregular body odor and combinations thereof.

[00154] According to an embodiment, the composition comprises less than 1% THC.

[00155] According to an embodiment, the composition comprises at least one phytoestrogen.

[00156] According to an embodiment, the composition comprises at least one of isoflavones, coumestans, prenylflavonoids, lignans and saponins.

[00157] According to an embodiment, the composition comprises at least one of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin and / or cimicifugoside.

[00158] According to an embodiment, the composition comprises caryophyllene, carene, borneol, thymol and / or camphor, and the therapeutic effect treats osteoporosis.

[00158] According to an embodiment, the composition comprises linalool, caryophyllene, myrcene, terpinene and / or borneol, and the therapeutic effect treats sleep disorder and / or insomnia. According to an embodiment, the composition includes caryophyllene, wherein caryophyllene, forms less than 5% by weight of the total terpene content.

[00159] According to an embodiment, the composition comprises limonene, linalool, eucalyptol, caryophyllene and / or myrcene, and the therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder. According to an embodiment, the composition includes pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene, wherein pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene forms less than 5% by weight of the total terpene content.

[00160] According to an embodiment, the composition comprises eucalyptol, pinene, carene, limonene and / or pulegone, and the therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss.

[00161] According to an embodiment, the composition comprises limonene, linalool, humulene, terpinene and / or caryophyllene, and the therapeutic effect treats general discomfort. According to an embodiment, the composition includes myrcene, pinene and / or bisabolol, wherein myrcene, pinene and / or bisabolol forms less than 5% by weight of the total terpene content.

[00162] According to an embodiment, the composition comprises myrcene, pinene, nerolidol, linalool and / or humulene, and the therapeutic effect treats muscle tension and / or myalgia.

[00163] According to an embodiment, the composition comprises pinene, terpinene, eucalyptol, myrcene and / or caryophyllene, and the therapeutic effect treats fatigue and / or intermittent dizziness.

[00164] According to an embodiment, the composition comprises linalool, terpineol, geraniol, citronellol and / or farnesol, and the therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks.

[00165] According to an embodiment, the composition comprises myrcene, linalool, caryophyllene, limonene and / or nerolidol, and the therapeutic effect treats headache and / or migraine. According to an embodiment, the composition includes bisabolol, terpinene, humulene and / or linalool wherein bisabolol, terpinene, humulene and / or linalool forms less than 5% by weight of the total terpene content.

[00166] According to an embodiment, the composition comprises eucalyptol, caryophyllene, limonene, humulene and / or phytol, and the therapeutic effect treats weight gain.

[00167] According to an embodiment, the composition comprises limonene, caryophyllene, sabinene, myrcene and / or linalool, and the therapeutic effect treats digestive problems, intestinal disorders, abdominal pain (colic), nausea, constipation and / or diarrhea. According to an embodiment, the composition includes pinene, bisabolol, limonene and / or terpineol, wherein pinene, bisabolol, limonene and / or terpineol forms less than 5% by weight of the total terpene content.

[00168] According to an embodiment, the composition comprises pinene, myrcene, linalool, eucalyptol and / or geraniol, and the therapeutic effect treats breast pain (Mastalgia).

[00169] According to an embodiment, the composition comprises myrcene, linalool, caryophyllene, eucalyptol and / or nerolidol, and the therapeutic effect treats dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and / or endometriosis.

[00170] According to an embodiment, the composition comprises myrcene, linalool, pinene, nerolidol and / or sabinene, and the therapeutic effect treats arthralgia and / or arthritis. According to an embodiment, the composition includes humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene, wherein humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene forms less than 5% by weight of the total terpene content.

[00171] According to an embodiment, the composition comprises linalool, terpineol, geraniol, citronellol and / or eucalyptol, and the therapeutic effect treats hot flashes, facial flushing, night sweat, irritability, palpitation and tachycardia.

[00172] According to an embodiment, the composition comprises caryophyllene, pinene, myrcene, eucalyptol and / or linalool, and the therapeutic effect treats inflammation, oxidative stress and / or paresthesia. According to an embodiment, the composition includes caryophyllene wherein caryophyllene forms less than 5% by weight of the total terpene content.

[00173] According to an embodiment, the composition comprises linalool, camphene, limonene, pinene and / or borneol, and the therapeutic effect treats cardiovascular disease, palpitation and tachycardia.

[00174] According to an embodiment, the composition comprises linalool, pinene, geraniol, caryophyllene and / or eucalyptol, and the therapeutic effect treats urine incontinence and / or lower urinary tract disorders.

[00175] According to an embodiment, the composition comprises linalool, terpineol, geraniol, pinene and / or eucalyptol, and the therapeutic effect treats vaginal dryness.

[00176] According to an embodiment, the composition comprises pinene, limonene, caryophyllene oxide, terpinene and / or geraniol, and the therapeutic effect treats female urogenital and / or reproductive system infection.

[00177] According to an embodiment, the composition comprises linalool, terpineol, limonene, pinene and / or terpinene and the therapeutic effect treats fibroid, myomas and / or cysts in the female genital system.

[00178] According to an embodiment, the composition comprises thujone, pinene, limonene, eucalyptol and / or linalool, and the therapeutic effect treats cystitis, urethritis and / or pyelonephritis.

[00179] According to an embodiment, the composition comprises limonene, linalool, terpineol, geraniol and / or eucalyptol, and the therapeutic effect treats reduced libido and / or sexual disfunction.

[00180] According to an embodiment, the composition comprises linalool, eucalyptol, geraniol, terpineol and / or pinene, and the therapeutic effect treats hair loss and / or thinning

[00181] According to an embodiment, the composition comprises linalool, eucalyptol, geraniol, pinene and / or limonene, and the therapeutic effect treats brittle nails.

[00182] According to an embodiment, the composition comprises linalool, terpineol, geraniol, and / or eucalyptol, and the therapeutic effect treats irregular body odor.

[00183] According to an embodiment, the composition comprises linalool, caryophyllene, geraniol, pinene and / or eucalyptol, and the therapeutic effect treats Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia

[00184] According to an embodiment, the composition comprises limonene, linalool, eucalyptol, geraniol and / or caryophyllene, and the therapeutic effect treats premenstrual syndrome (PMS), premenstrual tension, and / or premenstrual dysphoric disorder (PMDD)

[00185] According to an embodiment, the composition comprises linalool, geraniol, pinene, eucalyptol and / or limonene, and the therapeutic effect treats hormonal disfunction and / or imbalance and / or fertility

[00186] According to an embodiment, the composition comprises limonene, neral, caryophyllene, linalool and / or myrcene, and the therapeutic effect treats pre-eclampsia toxemia

[00187] According to an embodiment, the composition comprises linalool, terpineol, geraniol, pinene and / or eucalyptol, and the therapeutic effect treats conditions and / or symptoms associated with female hormonal disfunction and / or imbalance.

[00188] According to an embodiment, the composition comprises caryophyllene, carene, linalool, myrcene, limonene, and the therapeutic effect treats conditions and / or symptoms associated with perimenopause and / or menopause.

[00189] According to an embodiment, the composition comprises myrcene, linalool, eucalyptol, nerolidol and / or limonene, and the therapeutic effect treats pain and / or cramps.

[00190] According to an embodiment, the composition comprises linalool, pinene, caryophyllene oxide, borneol and / or eucalyptol, and the therapeutic effect treats female urogenital and / or reproductive system infections and / or disorders. Detailed description of the invention

[00191] Unless indicated otherwise the term menopausal as used herein refers to peri- menopausal, menopausal, or post-menopausal.

[00192] As used herein the term treat and / or treating refers to treating, healing, relieving, decreasing, preventing and / or reducing the risk of.

[00193] Unless indicated otherwise, percent is weight percent and ratio is weight / weight ratio. Unless indicated otherwise, weight ratio means the ratio between weight content, e.g. in an aqueous solution containing 20% solute and 80% water, the solute to water weight ratio is 20:80 or 1:4.

[00194] Unless indicated otherwise, the term cannabinoid refers to a compound that affects the endocannabinoid system. Cannabinoids are agonists or antagonists to receptors in the endocannabinoid system.

[00195] Unless indicated otherwise, female reproductive system refers to at least one of ovaries, fallopian tubes, uterus, vagina, vulva, mammary glands and / or breasts. Unless indicated otherwise, female reproductive system refers to organs that are involved in the production and transportation of gametes and the production of sex hormones.

[00196] Unless indicated otherwise, female urogential system refers to at least one of kidneys and ureters, bladder, urethra, uterus, fallopian tubes, ovaries, and / or vagina. Unless indicated otherwise, female reproductive system refers to organs that are involved in the production and transportation of gametes and the production of sex hormones

[00197] Unless indicated otherwise, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) refers to symptoms selected from the group of bloating, swollen painful breasts, fatigue, constipation, headaches, clumsiness, anger, anxiety, confusion, mood swings, tension, depression, inability to concentrate and combinations thereof.

[00198] Unless indicated otherwise, hormonal deficiency / hormonal imbalance / hormonal balancing refers to abnormal levels of estrogen and / or progesterone. Unless indicated otherwise, conditions and / or symptoms associated with female hormonal disfunction and / or imbalance include impaired fertility, Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).

[00199] Unless indicated otherwise, conditions and / or symptoms associated with perimenopause and / or menopause include hot flashes, facial flushing, night sweat, osteoporosis, fatigue, irritability, insomnia and / or sleep disorder, difficulty in concentration, depression, memory loss, brain fog, headache, migraine, anxiety, nervousness, restless, stress, mood swing, affect disorder, general discomfort, muscle tension, myalgia, intermittent dizziness, paresthesia, indigestion, digestive problems, intestinal disorders, abdominal pain, irritability, palpitations, tachycardia, nausea, constipation, diarrhea, arthralgia and / or arthritis, cold hands and feet, weight gain, mental awareness problems, sexual pain disorder, dyspareunia, breast pain and / or mastalgia, menopausal skin, inflammation, oxidative stress, cardiovascular disease, loss of pelvic muscle tone, urinary incontinence, vaginal dryness, reduced libido, reduced sexual dysfunction, hair loss and / or thinning, age-related winkles, stretch marks, brittle nails, gam disorders, irregular body odor, conditions and / or symptoms induced by estrogen deficiency and combinations thereof.

[00200] The particulars shown herein are by way of example and for purposes of illustrative discussion of the various embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

[00201] The present invention will now be described by reference to more detailed embodiments. This invention may, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.

[00202] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the invention and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[00203] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

[00204] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

[00205] Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

[00206] According to an embodiment, provided is a product for treating conditions and / or symptoms associated with women health comprising (i) at least one cannabinoid in a specific amount, (ii) a primary terpene in a specific amount, (iii) at least 5% by weight of a non- cannabinoid, non-terpene, carrier, (iv) optionally at least three secondary terpenes, (v) optionally at least one phytoestrogen; and (a) wherein the non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in the product is about 0.1 to about 1.0, or (b) wherein the non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight / weight ratio in the product is 0.05 to about 1.0, forming a terpene-enriched cannabinoid product with an enhanced therapeutic effect in treating conditions and / or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and / or disorders, menstrual cycle, hormonal deficiency and / or hormonal imbalance, compared with that of a product comprising the same cannabinoids amounts and one half the amount of said primary terpene. According to an embodiment, said product is a composition or the terms "product" and "composition are used interchangeably. According to an embodiment, said product comprises a composition comprising (i) at least one cannabinoid in a specific amount, (ii) a primary terpene in a specific amount, (iii) at least 5% by weight of a non-cannabinoid, non-terpene, carrier, (iv) optionally at least three secondary terpenes, (v) optionally at least one phytoestrogen; and (a) wherein the non- cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in the composition is about 0.1 to about 1.0, or (b) wherein the non- cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight / weight ratio in the composition is 0.05 to about 1.0. According to an embodiment, said product comprises a composition resulting from processing a plant material.

[00207] According to an embodiment, the enhanced therapeutic effect comprises a shortened onset time, increased magnitude, extended duration, reduced dosages, reduced secondary adverse symptoms, reduce frequency of conditions and / or symptoms, reduce severity of conditions and / or symptoms, reduce consumption of other drugs and combinations thereof.

[00208] According to an embodiment, the conditions and / or symptoms are selected from the group consisting of hot flashes, facial flushing, night sweat, osteoporosis, fatigue, irritability, insomnia and / or sleep disorder, difficulty in concentration, depression, memory loss, brain fog, headache, migraine, anxiety, nervousness, restless, stress, mood swing, affect disorder, general discomfort, muscle tension, myalgia, intermittent dizziness, paresthesia, indigestion, digestive problems, intestinal disorders, abdominal pain, irritability, palpitations, tachycardia, nausea, constipation, diarrhea, arthralgia and / or arthritis, dysmenorrheal, pelvic pain, spasms, cramps, labor contraction, endometriosis Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia, premenstrual syndrome (PMS), premenstrual tension, premenstrual dysphoric disorder (PMDD), cold hands and feet, weight gain, mental awareness problems, sexual pain disorder, dyspareunia, breast pain and / or mastalgia, menopausal skin, inflammation, oxidative stress, cardiovascular disease, loss of pelvic muscle tone, urinary incontinence, lower urinary tract disorders, vaginal dryness, women urogenital and / or reproductive system infection, fibroid, myomas and / or cysts in the female genital system, human papillomavirus (HPV), Uterine Fibroid, cystitis, urethritis, pyelonephritis, women hormonal dysfunction and / or imbalance, irregular periods, pre-eclampsia toxemia, reduced libido, reduced sexual dysfunction, hair loss and / or thinning, age-related winkles, stretch marks, brittle nails, gam disorders, irregular body odor, conditions and / or symptoms induced by estrogen deficiency and combinations thereof.

[00209] According to an embodiment, the product comprises at least two cannabinoids, at least three, at least four or at least five. According to an embodiment, the content of each cannabinoid in the product is at least 10 parts per million (ppm). As known in the art, cannabinoids have an acid form and a non-acid form (which is also referred to as decarboxylated form, since it can be generated by decarboxylating the acid form). The acid form is indicated herein by the letter (a) at the end of the cannabinoid acronym, e.g. tetrahydrocannabiniolic acid is indicated as THCa, while the decarboxylated form is THC. According to an embodiment, the cannabinoids are selected from the group consisting of tetrahydrocannabiniol in acid or decarboxylated form (THCa or THC, respectively), cannabidiol in acid or decarboxylated form (CBDa or CBD, respectively), cannabigerol in acid or decarboxylated form (CBGa or CBG, respectively), cannabichromene in acid or decarboxylated form (CBCa or CBC, respectively) tetrahydrocannabivarin in acid or decarboxylated form (THCVa or THCV, respectively), Cannabidivarin in acid or decarboxylated form (CBDVa or CBDV respectively), Cannabinol in acid or decarboxylated form (CBNa or CBN, respectively), Cannabicyclol in acid or decarboxylated form (CBLa or CBL, respectively). As used herein, the term THC refers to THCa (tetrahydrocannabiniolic acid) and / or to THC (tetrahydrocannabiniol) unless indicated otherwise. As used herein, the term CBD refers to CBDa (cannabidiolic acid) and / or to CBD (cannabidiol) unless indicated otherwise. As used herein, the term CBG refers to CBGa (cannabigerolic acid) and / or to CBG (cannabigerol) unless indicated otherwise. As used herein, the term CBN refers to CBNa (Cannabinolic acid) and / or to CBN (cannabinol) unless indicated otherwise. As used herein, the term CBC refers to CBCa (cannabichromenic acid) and / or to CBC (Cannabichromene) unless indicated otherwise. As used herein, the term CBL refers to CBLa (Cannabicycol acid) and / or to CBL (Cannabicyclol) unless indicated otherwise. As used herein, the term THCV refers to THCVa (tetrahydrocannabivarin acid) and / or to THCV (tetrahydrocannabivarin) unless indicated otherwise. As used herein, the term CBDV refers to CBDVa (cannabigerovarin acid) and / or to CBDV (cannabidivarin) unless indicated otherwise. Thus, the term "CBD to THC ratio" may mean "CBD to THC ratio", "CBDa to THC ratio", "CBD to THCa ratio", "CBDa to THCa ratio", "CBD to THC+THCa ratio", "CBDa to THC+THCa ratio", "CBD+CBDa to THC ratio", "CBD+CBDa to THCa ratio" or "CBD+CBDa to THC+THCa ratio".

[00210] According to an embodiment, at least one of the cannabinoids is in acid form. According to an embodiment, at least one of the cannabinoid is at least partially in decarboxylated form. According to an embodiment, at least 50% of the cannabinoid is in decarboxylated form, at least 60%, at least 70%, at least 80% or at least 90%.

[00211] According to an embodiment, the product comprises THC and / or THCa. According to an embodiment, the product comprises CBD and / or CBDa. According to an embodiment, the product comprises THC and / or THCa at a content of less than 1%, less than 0.8%, less than 0.6%, less than 0.4% or less than 0.2%. According to an embodiment, the product comprises both CBD and / or CBDa and THC and / or THCa and the weight / weight ratio between CBD and / or CBDa and THC and / or THCa ((CBD + CBDa) / (THC + THCa)) is at least 10, at least 15, at least 20, at least 25 or at least 30. According to an embodiment, the product comprises CBG and / or CBGa. According to an embodiment, the product comprises CBN and / or CBNa. According to an embodiment, the product comprises CBC and / or CBCa. According to an embodiment, the product comprises CBL and / or CBLa. According to an embodiment, the product comprises THCV and / or THCVa. According to an embodiment, the product comprises CBDV and / or CBDVa.

[00212] According to an embodiment, the product comprises at least 5% by weight carrier, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35% or at least 40% by weight. Any compound other than cannabinoids and terpenes is a suitable carrier. According to an embodiment, the carrier is selected from the group consisting of vegetable oils, e.g. coconut oil, olive oil or sesame oil, pharmaceutical excipients, honey, bees wax, cellulose and combinations thereof. As used herein, the term cellulose refers to cellulose, hemicellulose and their combinations.

[00213] According to an embodiment, the product comprises at least one phytoestrogen. According to an embodiment, the product comprises at least two, at least three, at least four, or at least five phytoestrogens.

[00214] According to an embodiment, the product comprises a primary terpene and optionally at least three secondary terpenes, at least four or at least five. The term "terpene", as used herein, refers to both terpenes and terpenoids. As used here, the term "primary terpene" refers to a terpene that forms at least 20% by weight of the total amount of terpenes in the product, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80%. According to an embodiment, the product comprises multiple (e.g. two or three) terpenes, each one of which forms at least 20% by weight of the total amount of terpenes in the product and each one of these terpenes is considered a primary terpene. As used here, the term "secondary terpene" refers to a terpene that forms at least 10 parts per million (ppm) of the product. According to an embodiment, the content of the primary terpene in the product is at least 2 times greater than that of any secondary terpene, at least 4, at least 6, at least 8, at least 10, at least 15, at least 20, at least 25, or at least 30 times greater.

[00215] As used herein, "terpenes / cannabinoids (or terpenes to cannabinoids) weight / weight ratio" means the weight ratio between the combined amount of terpenes and the combined amount of cannabinoids. According to an embodiment, the non-cannabinoid, non- terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in the product is about 0.1 to about 1.0. According to an embodiment said non-cannabinoid, non- terpene, carrier comprises at least 5% by weight cellulose, at least 6%, at least 8%, at least 10%, at least 15%, or at least 20%. According to an embodiment, the ratio is greater than 0.1, greater than 0.15, greater than 0.2, greater than 0.25, greater than 0.3, greater than 0.35, greater than 0.4, greater than 0.45, greater than 0.5, greater than 0.55, greater than 0.6, greater than 0.65, greater than 0.7, greater than 0.75, greater than 0.8, greater than 0.85, greater than 0.9, greater than 0.95, greater than 1, greater than 1.2, greater than 1.5, greater than 2.0, greater than 3 or greater than 5. According to an embodiment, the ratio is less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2 or less than 0.15. According to an embodiment, the product comprising more than 5% cellulose is selected from the group consisting of cannabis plant material, e.g. cannabis buds or cannabis trim, ground forms thereof, plant material preparation for vaporizers and cannabis cigarette.

[00216] According to another embodiment, the non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and terpenes to cannabinoids weight / weight ratio in the product is in the range between about 0.05 and about 1.0. According to an embodiment said non-cannabinoid, non-terpene, carrier comprises less than 5% by weight cellulose, less than 4%, less than 3%, less than 2%, or less than 1% cellulose. According to an embodiment, the ratio is greater than 0.1, greater than 0.15, greater than 0.2, greater than 0.25, greater than 0.3, greater than 0.35, greater than 0.4, greater than 0.45, greater than 0.5, greater than 0.55, greater than 0.6, greater than 0.65, greater than 0.7, greater than 0.75, greater than 0.8, greater than 0.85, greater than 0.9, greater than 0.95, greater than 1, greater than 1.2, greater than 1.5, greater than 2.0, greater than 3 or greater than 5. According to an embodiment, the ratio is less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2, less than 0.15 or less than 0.1. According to an embodiment, the product comprising less than 5% cellulose is selected from the group consisting of cannabis trichomes, cannabis extracts and products thereof, such as tablets, gel capsules, medical patches, topicals, creams, varnishes, sublingual oils, sprays, edibles, suppositories, tampons, rectal candles, cigarettes, vaporizer liquids nasal preparation, preparations containing micro and nano-emulsions, preparations containing micro and nano-particles and combinations thereof.

[00217] According to an embodiment, the primary terpene, the secondary terpenes or both are selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol, isomers thereof and combinations thereof. According to an embodiment, the primary terpene the secondary terpenes or both, are selected from the group consisting of pinene, limonene, linalool, caryophyllene, myrcene, terpineol, eucalyptol, geraniol and combinations thereof. According to an embodiment, the primary terpene the secondary terpenes or both, are selected from the group consisting of pinene, limonene, linalool, caryophyllene, myrcene, eucalyptol and combinations thereof. According to an embodiment, at least one of the terpenes is a-cyclic. According to an embodiment, at least one of the terpenes is cyclic. According to an embodiment, at least one of the terpenes is not found in cannabis buds or is present there at less than 0.2%, less than 0.1%, less than 0.05% or less than 0.02%. Such terpene is referred to as "non-cannabis terpene". According to an embodiment, the terpene-enriched cannabinoid product comprises the non-cannabis terpene at a concentration of at least 0.2%, at least 0.5%, least 0.8%, at least 1%, least 1.5%, at least 2%, at least 3%, least 4%, at least 5%, at least 8% or at least 12%.

[00218] According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1- ol, farensol, carotol, myrtenol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, myrcene, terpineol, eucalyptol, geraniol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, myrcene, eucalyptol and combinations thereof. According to an embodiment, the primary terpene is a non-cannabis terpene.

[00219] According to an embodiment, the terpenes comprise at least one monoterpene selected from the group consisting of limonene, myrcene, pinene, linalool, geraniol, terpinene camphene and isomers thereof. According to an embodiment, the terpenes comprise at least one sesquiterpene selected from the group consisting of nerolidol, caryophyllene, farnesene, zingiberene, vetivazulene, guaiazulene, longifolene, copaene, patchoulol humulene and isomers thereof. According to an embodiment, the terpenes comprise at least one diterpene selected from the group consisting of phytol, retinal, retinol, phytane, cembrene, sclarene, labdane, abietane, texadiene, stemarene, stemoden and isomers thereof. According to an embodiment, the terpenes comprise at least one hydroxy-terpene selected from the group consisting of nerolidol, geraniol, linalool, phytol and isomers thereof. As used herein "hydroxy-terpene" refers to a terpene carrying a hydroxyl function.

[00220] According to an embodiment, at least one of the terpenes is a monoterpene, at least one of the terpenes is a sesquiterpene and the monoterpenes to sesquiterpenes weight / weight ratio (i.e. the weight ratio between the total amount of monoterpenes and the total amount of the sesquiterpenes) is greater than 1.5 greater than 2, greater than 2.5, greater than 3, greater than 3.5, greater than 4, greater than 4.5, greater than 5, greater than 6, greater than 7, greater than 8, greater than 9, greater than 10, greater than 15, or greater than 20.

[00221] According to an embodiment, at least one of the terpenes is a monoterpene, at least one of the terpenes is a diterpene and the monoterpenes to diterpenes weight / weight ratio (i.e. the weight ratio between the total amount of monoterpenes and the total amount of the diterpenes) is greater than 5, greater than 6, greater than 7, greater than 8, greater than 9, greater than 10, greater than 12, greater than 14, greater than 16, greater than 18, greater than 20, greater than 25, or greater than 30.

[00222] According to an embodiment, at least one of the terpenes carries no hydroxyl group, at least one of the terpenes carries hydroxyl group and the non-hydroxy-terpenes to hydroxyl- terpenes weight / weight ratio (i.e. the weight ratio between the total amount of non-hydroxy- terpenes and the total amount of the hydroxy-terpenes) is greater than 1.5, greater than 2, greater than 2.5, greater than 3, greater than 3.5, greater than 4, greater than 4.5, greater than 5, greater than 6, greater than 7, greater than 8, greater than 9, greater than 10, greater than 15, or greater than 20.

[00223] According to an embodiment, terpenes form at least 0.5% by weight of the product, at least 1%, at least 2%, at least 3%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60% or at least 70%.

[00224] According to an embodiment, the product comprises a composition, which is liquid at 30°C. According to an embodiment, the product comprises a composition, which is a suspension at 30°C. According to an embodiment, the product comprises a composition, which is essentially clear of haze or suspended solids at 30°C.

[00225] According to an embodiment, the product comprises cannabis plant material. According to an embodiment, the product comprises cannabis bud. According to an embodiment, the cannabis bud forms at least 20% of the product, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80%.

[00226] According to an embodiment, the non-cannabinoid, non-terpene, carrier comprises cellulose, and the product comprises (a) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 5% by weight; (b) cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 5% by weight; (c) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 2.5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 2.5% by weight; or (d) at least one of cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and cannabicyclol (CBL), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), and non-decarboxylated form thereof in a concentration of at least 0.5% by weight; and (i) the primary terpene forms at least 40% by weight of the total terpene content, and (ii) the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1- ol, farensol, carotol, myrtenol and combinations thereof.

[00227] According to an embodiment, the non-cannabinoid, non-terpene, carrier comprises cellulose, and the product comprises (a) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 5% by weight; (b) cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 5% by weight; or (c) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 2.5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 2.5% by weight; and optionally (d) at least one of cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and cannabicyclol (CBL), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), and non-decarboxylated form thereof in a concentration of at least 0.5% by weight; wherein (i) the primary terpene forms at least 40% by weight of the total terpene content, and (ii) the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1- ol, farensol, carotol, myrtenol and combinations thereof.

[00228] According to a related embodiment said non-cannabinoid, non-terpene, carrier comprises at least 5% by weight cellulose, at least 6%, at least 8%, at least 10%, at least 15%, or at least 20%.

[00229] According to a related embodiment said tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) is in a total concentration of at least 4% by weight, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18%, or at least 20% by weight.

[00230] According to a related embodiment said cannabidiol (CBD) and / or cannabidiolic acid (CBDa) is in a total concentration of at least 4% by weight, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20% by weight.

[00231] According to a related embodiment, said product comprises tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 2.5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 2.5% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 3% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 3% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 4% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 4% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 5% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 8% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 8% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 10% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 10% by weight.

[00232] According to a related embodiment, said product comprises cannabigerol (CBG) and / or cannabigerol acid (CBGa) in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises cannabinol (CBN) and / or cannabinol acid (CBNa) in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises cannabichromene (CBC) and / or cannabichromenic acid (CBCa) in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises cannabicyclol (CBL) and / or cannabicyclol acid (CBLa) in a total concentration at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises tetrahydrocannabivarin (THCV), and / or tetrahydrocannabivarin acid (THCVA) in a total concentration at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises cannabidivarin (CBDV) and / or cannabigerovarin acid (CBGVA) in a total concentration at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight.

[00233] According to a related embodiment, said primary terpene forms at least 20% by weight of the total terpene content, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% by weight of the total terpene content. According to a related embodiment, said primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof. According to a related embodiment, said product comprises a dried cannabis plant material. According to a related embodiment, said product comprises ground cannabis plant material, is a vaporizer cannabis filling material or is a cannabis cigarette.

[00234] According to an embodiment, the product comprises (a) at least one cannabinoid from the group consisting of THC, CBD, CBG, CBC, CBN, CBL THCV, CBDV and their non- decarboxylated form thereof; (b) a non-cannabinoid, non-terpene carrier, comprising less than 5% by weight cellulose; (c) a primary terpene, forming at least 40% by weight of the total terpene content, wherein the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[00235] According to a related embodiment said THC and / or THCa is in a total concentration of at least 1% by weight, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00236] According to a related embodiment said CBD and / or CBDa is in a total concentration of at least 1% by weight, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00237] According to a related embodiment said CBG and / or CBGa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00238] According to a related embodiment said CBC and / or CBCa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00239] According to a related embodiment said CBN and / or CBNa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00240] According to a related embodiment said CBL and / or CBLa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00241] According to a related embodiment said THCV and / or THCVa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00242] According to a related embodiment said CBDV and / or CBDVa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00243] According to a related embodiment said non-cannabinoid non-terpene carrier comprises less than 5% by weight cellulose, less than 4%, less than 3%, less than 2%, or less than 1%, or less than 0.5% by weight cellulose.

[00244] According to a related embodiment, said primary terpene forms at least 20% by weight of the total terpene content, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% by weight of the total terpene content. According to a related embodiment, said primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof. According to an embodiment, said product comprises a liquid. According to an embodiment, said product is selected from the group consisting of tablets, gel capsules, medical patches, topicals, creams, varnish, sublingual oil, sprays, edibles, cannabis candies, cannabis drinks, cannabis baked products, suppositories, tampons, rectal candle, cigarettes, vaporizer liquid, nasal preparartion, preparations containing micro and nano- emulsions, preparations containing micro and nano-particles and combinations thereof.

[00245] According to an embodiment, the product comprises less than 5% by weight glycol, less than 4%, less than 3%, less than 2%, or less than 1%, by weight glycol. As used herein, the term glycol refers to any glycol, including ethylene glycol, polyethylene glycol, propylene glycol and polypropylene glycol.

[00246] According to an embodiment, the product comprises water and water content is less than 30% by weight, less than 25%, less than 20%, less than 15%, less than 12%, less than 10%, or less than 8%. According to an embodiment, water content is at least 1% by weight, at least 2%, at least 3%, at least 4% or at least 5% by weight.

[00247] According to an embodiment, the product comprises chlorophyll. According to an embodiment, the product comprises at least 0.5% chlorophyll, at least 1, %at least 5%, at least 10%, at least 15%, at least 20% chlorophyll. According to an embodiment, the product comprises at least one flavonoid. According to an embodiment, the product comprises at least two, at least three, at least four, or at least five flavonoids. According to an embodiment, the product comprises at least one of isoflavones, coumestans, prenylflavonoids, lignans and saponins. According to an embodiment, the product comprises isoflavones. According to an embodiment, the product comprises coursestans. According to an embodiment, the product comprises prenylflavonoids. According to an embodiment, the product comprises lignans. According to an embodiment, the product comprises saponins. According to an embodiment, the product comprises at least one of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin and / or cimicifugoside. According to an embodiment, the product comprises biochanin A. According to an embodiment, the product comprises formonenetin. According to an embodiment, the product comprises genistein. According to an embodiment, the product comprises daidzein. According to an embodiment, the product comprises glycitein. According to an embodiment, the product comprises prenylnaringenin. According to an embodiment, the product comprises diosgenin. According to an embodiment, the product comprises acetin. According to an embodiment, the product comprises cimicifugoside.

[00248] According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[00249] According to an embodiment, the product results in an increased therapeutic effect compared with that of a product comprising the same cannabinoids amounts and a smaller amount of the primary terpene, e.g. one half of that amount. According to various embodiment, the increased therapeutic effect has various forms, e.g. a shorter onset time, increased magnitude, extended duration, reduced dosages, reduced secondary adverse symptoms, reduced frequency of conditions and / or symptoms, reduced severity of conditions and / or symptoms, reduced consumption of other drugs and combinations thereof. According to an embodiment, the increased therapeutic effect comprises a shorter onset time, or differently put an earlier effect, which is important particularly in cases of sublingual and topical delivery and in cases where a rapid effect is desired, as in treating pain. According to an embodiment, the increased therapeutic effect comprises extended duration of the therapeutic effect, for example an extended time of pain relief. According to an embodiment, the increased therapeutic effect comprises increased magnitude of the therapeutic effect, enabling achieving a desired therapeutic effect on administering smaller doses of cannabinoids, saving thereby on cost. According to an embodiment, the increased therapeutic effect comprises using smaller doses of cannabinoids and still achieving at least the same beneficial result. According to an embodiment, the increased therapeutic effect comprises reduction of secondary adverse symptoms, e.g. adverse symptoms of the main illness, of ones of another illness and / or ones related to administered the product or other drugs. According to an embodiment, the increased therapeutic effect comprises reduced frequency of the conditions and / or symptoms. According to an embodiment, the increased therapeutic effect comprises reduced severity of the conditions and / or symptoms.

[00250] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect, as measured by methods known in the art, is at least 20% shorter than that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% shorter. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect is at least 20% shorter than that of a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% short. Shorter onset time, or differently put an earlier effect, is important particularly in cases of sublingual and topical delivery and in cases where a rapid effect is desired, as in treating pain.

[00251] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect is at least 20% longer than that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% longer. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect is at least 20% longer than that of a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% longer. According to an embodiment, products of delayed onset time are used in combination with shorter onset time to reach a sustained release effect.

[00252] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the magnitude of the therapeutic effect, as measured by methods known in the art, is at least 20% greater compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% greater. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the magnitude of the therapeutic effect is at least 20% greater than that of a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% greater. Without wishing to be limited by any particular theory, such increased magnitude of the therapeutic effect may indicate increased bioavailability. Such increased magnitude enables achieving a desired therapeutic effect on administering smaller doses of cannabinoids, saving thereby on cost.

[00253] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the duration of the therapeutic effect, as measured by methods known in the art, is at least 20% longer compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% longer. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the duration of the therapeutic effect is at least 20% longer than that of a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% longer.

[00254] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the frequency of the conditions and / or symptoms, as measured by methods known in the art, is at least 20% smaller compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50% at least 60%, at least 70%, at least 80%, or at least 90% smaller. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the frequency of the conditions and / or symptoms, as measured by methods known in the art, is at least 20% smaller than that of a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% longer.

[00255] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the severity of the conditions and / or symptoms, as measured by methods known in the art, is at least 20% smaller compared with that of a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50% at least 60%, at least 70%, at least 80%, or at least 90% smaller. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the severity of the conditions and / or symptoms, as measured by methods known in the art, is at least 20% smaller than that of a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% smaller.

[00256] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the consumption of other drugs is reduced by at least 20% compared with that of a product comprising the same cannabinoids amounts and one half the amount of said primary terpene, reduced by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 80%, or by at least 90%. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the consumption of other drugs, as measured by methods known in the art, is reduced by at least 20% compared with a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, reduced by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 80%, or by at least 90%.

[00257] According to an embodiment, the therapeutic effect is generated while administering the product in a vaporizer. According to an embodiment, the therapeutic effect is generated while administering the product by inhaling. According to an embodiment, the therapeutic effect is generated while administering the product by smoking. According to an embodiment, the therapeutic effect is generated while administering the product sublingually. According to an embodiment, the therapeutic effect is generated while applying the product, topically. According to an embodiment, the therapeutic effect is generated while administering the product in suppositories, including tampons and / or rectal candles. According to an embodiment, the therapeutic effect is generated while administering the product in a spray. According to an embodiment, the therapeutic effect is generated while administering the product as an edible, as a candy, as baked good, as a drink. According to an embodiment, the therapeutic effect is generated while administering the product as vaporizer liquid nasal preparation. According to an embodiment, the therapeutic effect is generated while administering the product as micro and nano-emulsions. According to an embodiment, the therapeutic effect is generated while administering the product as micro and nano-emulsions.

[00258] According to an embodiment said therapeutic effect treats osteoporosis and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats osteoporosis and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats osteoporosis and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats osteoporosis and said the primary terpene is selected from the group consisting of caryophyllene, caryophyllene oxide, carene, eucalyptol, sabinene, pinene, limonene, borneol, thymol, camphor and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene, carene, borneol and combinations thereof. According to various embodiments said primary terpene comprises caryophyllene oxide, eucalyptol, sabinene, pinene, limonene, thymol and / or camphor. According to an embodiment, said therapeutic effect treats osteoporosis and the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00259] According to an embodiment said therapeutic effect treats sleep disorder and / or insomnia and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats sleep disorder and / or insomnia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats sleep disorder and / or insomnia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats sleep disorder and / or insomnia and said the primary terpene is selected from the group consisting of linalool, caryophyllene, myrcene, terpineol, terpinene, citronellol, eucalyptol, nerolidol, sabinene, pinene, limonene, borneol, fenchol, bisabolol humulene, phytol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, caryophyllene, myrcene and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, nerolidol, myrcene and combinations thereof. According to various embodiments said primary terpene comprises terpineol, terpinene, citronellol, eucalyptol, nerolidol, sabinene, pinene, limonene, borneol, fenchol, bisabolol, phytol and / or humulene. According to an embodiment, said therapeutic effect treats sleep disorder and / or insomnia and the product further comprises a compound selected from the group consisting of linalyl acetate, chamazulene, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, the product includes caryophyllene, and caryophyllene forms less than 5% by weight of the total terpene content.

[00260] According to an embodiment said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and said the primary terpene is selected from the group consisting of limonene, linalool, terpineol, citronellol, eucalyptol, caryophyllene, geraniol, menthol, iso-menthone, germacrene, pinene, citronellol, cardinol, neral, geranial, myrcene, terpinene, menth-2-en-l-ol, humulene, bisabolol, borneol, fenchol, nerolidol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, eucalyptol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, caryophyllene, bisabolol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, pinene, humulene and combinations thereof. According to various embodiments said primary terpene comprises terpineol, citronellol, caryophyllene, geraniol, menthol, iso-menthone, germacrene, pinene, citronellol, cardinol, neral, geranial, myrcene, terpinene, menth-2-en-l-ol, humulene, bisabolol, borneol, nerolidol or fenchol. According to an embodiment, said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, menthol, piperine, eugenol, citronelly formate, jasmone, benzy acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, the product includes pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene, and pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene forms less than 5% by weight of the total terpene content.

[00261] According to an embodiment said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and said the primary terpene is selected from the group consisting of eucalyptol, pinene, carene, limonene, pulegone, terpineol, cymene, linalool, caryophyllene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of eucalyptol, pinene, limonene and combinations thereof. According to various embodiments said primary terpene comprises carene, pulegone, terpineol, linalool, caryophyllene and / or cymene According to an embodiment, said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00262] According to an embodiment said therapeutic effect treats general discomfort and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats general discomfort and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats general discomfort and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats general discomfort and said the primary terpene is selected from the group consisting of limonene, linalool humulene, terpinene, borneol, caryophyllene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, humulene, terpinene and combinations thereof. According to various embodiments said primary terpene comprises limonene, borneol and / or caryophyllene. According to an embodiment, the product includes myrcene, pinene and / or bisabolol, and myrcene, pinene and / or bisabolol forms less than 5% by weight of the total terpene content.

[00263] According to an embodiment said therapeutic effect treats muscle tension and / or myalgia and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats muscle tension and / or myalgia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats muscle tension and / or myalgia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats muscle tension and / or myalgia and said the primary terpene is selected from the group consisting of myrcene, pinene, nerolidol, linalool, humulene, caryophyllene, limonene, bisabolol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of myrcene, pinene, nerolidol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of myrcene, pinene, nerolidol, linalool, humulene and combinations thereof. According to various embodiments said primary terpene comprises linalool, humulene, caryophyllene, limonene and / or bisabolol.

[00264] According to an embodiment said therapeutic effect treats fatigue and / or intermittent dizziness and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats fatigue and / or intermittent dizziness and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats fatigue and / or intermittent dizziness and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats fatigue and / or intermittent dizziness and said the primary terpene is selected from the group consisting of pinene, limonene, terpinene, eucalyptol, myrcene, terpineol, linalool, caryophyllene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, eucalyptol and combinations thereof. According to various embodiments said primary terpene comprises terpinene, myrcene and / or caryophyllene.

[00265] According to an embodiment said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks and said the primary terpene is selected from the group consisting of linalool limonene, nerolidol, pinene terpineol, myrcene, geraniol, nerol, citronellol, farnesol, carotol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, terpineol, geraniol and combinations thereof. According to various embodiments said primary terpene comprises limonene, nerolidol, pinene myrcene, nerol, citronellol, farnesol and / or carotol. According to an embodiment, said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks and the product further comprises a compound selected from the group consisting of linally acetate, citronelly formate, eugenol, benzy acetate, benzyl alcohol, biochanin Α, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00266] According to an embodiment said therapeutic effect treats headache and / or migraine and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats headache and / or migraine and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats headache and / or migraine and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats headache and / or migraine and said the primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, limonene, nerolidol, fenchol, humulene, guaiol, borneol, pinene, bisabolol, terpinene, terpineol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene and combinations thereof. According to various embodiments said primary terpene comprises eucalyptol, limonene, nerolidol, fenchol, humulene, guaiol, linalool, limonene, borneol, pinene and / or bisabolol. According to an embodiment, the product includes bisabolol, terpinene, humulene and / or linalool wherein bisabolol, terpinene, humulene and / or linalool forms less than 5% by weight of the total terpene content.

[00267] According to an embodiment said therapeutic effect treats weight gain and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats weight gain and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats weight gain and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats weight gain and said the primary terpene is selected from the group consisting of eucalyptol, caryophyllene, limonene, humulene, phytol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of eucalyptol, limonene, humulene and combinations thereof. According to various embodiments said primary terpene comprises caryophyllene and / or phytol.

[00268] According to an embodiment said therapeutic effect treats digestive problems, intestinal disorders, abdominal pain (colic), nausea, constipation and / or diarrhea and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats digestive problems, intestinal disorders, abdominal pain (colic), nausea, constipation and / or diarrhea and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats digestive problems, intestinal disorders, abdominal pain (colic), nausea, constipation and / or diarrhea and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats digestive problems, intestinal disorders, abdominal pain (colic), nausea, constipation and / or diarrhea and said the primary terpene is selected from the group consisting of limonene, cymene, terpinene, caryophyllene, citronellol, sabinene, myrcene, linalool, germacrene, geraniol, pinene, terpineol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of limonene, sabinene, myrcene and combinations thereof. According to various embodiments said primary terpene comprises cymene, terpinene, caryophyllene, citronellol, linalool, germacrene, geraniol, terpineol and / or pinene. According to an embodiment, said therapeutic effect treats digestive problems, intestinal disorders, abdominal pain (colic), nausea, constipation and / or diarrhea and the product further comprises piperine. According to an embodiment, the product includes pinene, bisabolol, limonene and / or terpineol, wherein pinene, bisabolol, limonene and / or terpineol forms less than 5% by weight of the total terpene content

[00269] According to an embodiment said therapeutic effect treats breast pain and / or Mastalgia and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats breast pain and / or Mastalgia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats breast pain and / or Mastalgia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats pain and / or Mastalgia and said the primary terpene is selected from the group consisting of pinene, limonene, caryophyllene, myrcene, linalool, geraniol, eucalyptol, terpineol, sabinene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of pinene, linalool, eucalyptol and combinations thereof. According to various embodiments said primary terpene comprises limonene, caryophyllene, myrcene, geraniol, terpineol and / or sabinene. According to an embodiment, said therapeutic effect treats pain and / or Mastalgia and the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00270] According to an embodiment said therapeutic effect treats dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and / or endometriosis and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and / or endometriosis and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and / or endometriosis and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and / or endometriosis and said the primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, limonene, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso-menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2-en-l-ol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, eucalyptol, nerolidol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, myrcene, nerolidol and combinations thereof. According to various embodiments said primary terpene comprises myrcene, caryophyllene, limonene, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso- menthone, carvacrol, thymol, carene, nerol, farnesol and / or menth-2-en-ol. According to an embodiment, said therapeutic effect treats dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and / or endometriosis and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, methylis-oeugenol, menthol, eugenyl acetate, piperine, chamazulene, citronllyl formate, benzyl acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00271] According to an embodiment said therapeutic effect treats arthralgia and / or arthritis and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats arthralgia and / or arthritis and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats arthralgia and / or arthritis and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats arthralgia and / or arthritis and said the primary terpene is selected from the group consisting of myrcene, linalool, guaiol, caryophyllene, eucalyptol, pinene, nerolidol, sabinene, limonene, terpinene, menth-2-en-l-ol, geraniol, guaiol, humulene, bisabolol, borneol, fenchol, terpineol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of myrcene, pinene, sabinene and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of terpineol, linalool, sabinene and combinations thereof. According to various embodiments said primary terpene comprises linalool, guaiol, caryophyllene, eucalyptol, nerolidol, limonene, terpinene, menth-2-en-l-ol, geraniol, guaiol, humulene, bisabolol, borneol, fenchol and / or terpineol. According to an embodiment, said therapeutic effect treats arthralgia and / or arthritis and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, methylis-oeugenol, menthol, eugenyl acetate, piperine and combinations thereof. According to an embodiment, the product optionally includes humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene, wherein humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, ocimene, terpineol, terpinene and / or caryophyllene forms less than 5% by weight of the total terpene content.

[00272] According to an embodiment said therapeutic effect treats hot flashes, facial flushing, night sweat, irritability, palpitation and / or tachycardia and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats hot flashes, facial flushing, night sweat, irritability, palpitation and / or tachycardia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats hot flashes, facial flushing, night sweat, irritability, palpitation and / or tachycardia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats hot flashes, facial flushing, night sweat, irritability, palpitation and / or tachycardia and said the primary terpene is selected from the group consisting of caryophyllene, myrcene, humulene, linalool, terpineol, geraniol, pinene, carene, citronellol, limonene, eucalyptol, sabinene, myrtenol, terpinene, champhene, borneol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, pinene, eucalyptol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, geraniol, limonene, eucalyptol and combinations thereof. According to various embodiments said primary terpene comprises caryophyllene, myrcene, humulene, terpineol, geraniol, pinene, carene, citronellol, limonene, sabinene, myrtenol, champhene, borneol and / or terpinene. According to an embodiment, said therapeutic effect treats hot flashes, facial flushing, night sweat, irritability, palpitation and / or tachycardia and the product further comprises a compound selected from the group consisting of linalyl acetate, geranyl acetate, citronellyl formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00273] According to an embodiment said therapeutic effect treats inflammation, oxidative stress and / or paresthesia and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats inflammation, oxidative stress and / or paresthesia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats inflammation, oxidative stress and / or paresthesia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats inflammation, oxidative stress and / or paresthesia and said the primary terpene is selected from the group consisting of caryophyllene, pinene, myrcene, limonene, humulene, citronellol, eucalyptol, linalool, beta amyrin, cycloartenol, terpinene, terpineol, geraniol, carvacrol, thymol, cardinol, terpinene, menth-2-en-l-ol, carotol, humulene, nerolidol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene, pinene, eucalyptol and combinations thereof. According to various embodiments said primary terpene comprises myrcene, limonene, humulene, citronellol, linalool, beta amyrin, cycloartenol, terpinene, terpineol, geraniol, carvacrol, thymol, cardinol, terpinene, menth-2-en-l-ol, carotol, humulene and / or nerolidol. According to an embodiment, said therapeutic effect treats inflammation, oxidative stress and / or paresthesia and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, eugenyl acetate, piperine and combinations thereof.

[00274] According to an embodiment said therapeutic effect treats cardiovascular disease, palpitation and tachycardia and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats cardiovascular disease, palpitation and tachycardia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats cardiovascular disease, palpitation and tachycardia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats cardiovascular disease, palpitation and tachycardia and said the primary terpene is selected from the group consisting of linalool, camphene, limonene, pinene, borneol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or all 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, limonene, pinene and combinations thereof. According to various embodiments said primary terpene comprises camphene and / or borneol.

[00275] According to an embodiment said therapeutic effect treats urine incontinence and / or lower urinary tract disorders and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats urine incontinence and / or lower urinary tract disorders and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats urine incontinence and / or lower urinary tract disorders and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats urine incontinence and / or lower urinary tract disorders and said the primary terpene is selected from the group consisting of linalool, terpineol, pinene, carene, geraniol, thujone, camphor, viridiflorol, caryophyllene, germacrene, cirtonellol, eucalyptol, myrtenol, sanatalol, sabinene, limonene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, geraniol, pinene and combinations thereof. According to various embodiments said primary terpene comprises terpineol, carene, thujone, camphor, viridiflorol, caryophyllene, germacrene, cirtonellol, eucalyptol, myrtenol, sanatalol, sabinene and / or limonene According to an embodiment, said therapeutic effect treats urine incontinence and / or lower urinary tract disorders and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate and combinations thereof.

[00276] According to an embodiment said therapeutic effect treats vaginal dryness and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats vaginal dryness and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats vaginal dryness and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats vaginal dryness and said the primary terpene is selected from the group consisting of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l- ol, eucalyptol, myrtenol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, geraniol, pinene and combinations thereof. According to various embodiments said primary terpene myrcene, humulene, caryophyllene, terpineol, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l-ol, eucalyptol and / or myrtenol According to an embodiment, said therapeutic effect treats vaginal dryness and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00277] According to an embodiment said therapeutic effect treats female urogenital and / or reproductive system infection and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats female urogenital and / or reproductive system infection and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats female urogenital and / or reproductive system infection and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats female urogenital and / or reproductive system infection and said the primary terpene is selected from the group consisting of pinene, limonene, cymene, caryophyllene oxide, ocimene, nerolidol, eucalyptol, terpinene, terpineol, camphor, linalool, sabinene, thujone, camphor, viridiflorol, menthol, iso-menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, myrcene, menth-2-en-l-ol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene oxide, pinene, limonene, geraniol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene oxide, pinene, limonene and combinations thereof. According to various embodiments said primary terpene comprises cymene, ocimene, nerolidol, eucalyptol, terpinene, terpineol, camphor, linalool, sabinene, thujone, camphor, viridiflorol, menthol, iso-menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, myrcene and / or menth-2-en-l-ol. According to an embodiment, said therapeutic effect treats female urogenital and / or reproductive system infection and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, eugenyl acetate, piperine, menthol, citronellyl formate and combinations thereof. According to an embodiment the therapeutic effect treats human papillomavirus (HPV).

[00278] According to an embodiment said therapeutic effect treats fibroid, myomas and / or cysts in the female genital system and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats fibroid, myomas and / or cysts in the female genital system and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats fibroid, myomas and / or cysts in the female genital system and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats fibroid, myomas and / or cysts in the female genital system and said the primary terpene is selected from the group consisting of linalool, terpineol, limonene, pinene, caryophyllene, caryophyllene oxide, terpinene, citronellol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of limonene, pinene, terpinene and combinations thereof. According to various embodiments said primary terpene comprises linalool, terpineol, caryophyllene, caryophyllene oxide and / or citronellol.

[00279] According to an embodiment said therapeutic effect treats cystitis, urethritis and / or pyelonephritis and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats cystitis, urethritis and / or pyelonephritis and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats cystitis, urethritis and / or pyelonephritis and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats cystitis, urethritis and / or pyelonephritis and said the primary terpene is selected from the group consisting of thujone, pinene, limonene, cymene, caryophyllene, caryophyllene oxide, eucalyptol, terpineol, sabinene, linalool, cardinol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of limonene, eucalyptol, linalool and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of limonene, pinene, linalool and combinations thereof. According to various embodiments said primary terpene comprises thujone, pinene, cymene, caryophyllene, caryophyllene oxide, terpineol, sabinene and / or cardinol.

[00280] According to an embodiment said therapeutic effect treats libido and / or sexual disfunction and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats libido and / or sexual disfunction and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats libido and / or sexual disfunction and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats libido and / or sexual disfunction and said the primary terpene is selected from the group consisting of limonene, linalool, terpineol, geraniol, eucalyptol, pinene, citronellol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, ecualyptol and combinations thereof. According to various embodiments said primary terpene comprises terpineol, geraniol and / or pinene. According to an embodiment, said therapeutic effect treats libido and / or sexual disfunction and the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00281] According to an embodiment said therapeutic effect treats hair loss and / or thinning and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats hair loss and / or thinning and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats hair loss and / or thinning and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats hair loss and / or thinning and said the primary terpene is selected from the group consisting of linalool, terpineol, eucalyptol, borneol, camphor, pinene, geraniol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of geraniol, eucalyptol, terpineol and combinations thereof. According to various embodiments said primary terpene comprises linalool, borneol, camphor and / or pinene.

[00282] According to an embodiment said therapeutic effect treats brittle nails and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats brittle nails and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats brittle nails and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats brittle nails and said the primary terpene is selected from the group consisting of linalool, eucalyptol, geraniol, pinene, limonene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or all 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linabool, eucalyptol, limonene and combinations thereof. According to various embodiments said primary terpene comprises geraniol and / or pinene.

[00283] According to an embodiment said therapeutic effect treats irregular body odor and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats irregular body odor and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats irregular body odor and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats irregular body odor and said the primary terpene is selected from the group consisting of linalool, terpineol, geraniol, eucalyptol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, or all 4 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, terpineol, geraniol and combinations thereof.

[00284] According to an embodiment said therapeutic effect treats Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia and said the primary terpene is selected from the group consisting of humulene, linalool, terpineol, caryophyllene, caryophyllene oxide, terpinene, citronellol, geraniol, thujone, camphor, viridiflorol, pinene, camphene, sabinene, myrcene, eucalyptol, carene, carotol, limonene, sabinene, cardinal, pinene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, eucalyptol, geraniol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, eucalyptol, caryophyllene, pinene and combinations thereof. According to various embodiments said primary terpene comprises humulene, terpineol, caryophyllene, caryophyllene oxide, terpinene, citronellol, thujone, camphor, viridiflorol, pinene, camphene, sabinene, myrcene, carene, carotol, limonene, sabinene, cardinal and / or pinene. According to an embodiment, said therapeutic effect treats Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, chamazulene, citronellyl formate and combinations thereof.

[00285] According to an embodiment said therapeutic effect treats premenstrual syndrome (PMS), premenstrual tension, and / or premenstrual dysphoric disorder (PMDD) and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats premenstrual syndrome (PMS), premenstrual tension, and / or premenstrual dysphoric disorder (PMDD) and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats premenstrual syndrome (PMS), premenstrual tension, and / or premenstrual dysphoric disorder (PMDD) and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats premenstrual syndrome (PMS), premenstrual tension, and / or premenstrual dysphoric disorder (PMDD) and said the primary terpene is selected from the group consisting of limonene, linalool, eucalyptol, nerolidol, sabinene, pinene, caryophyllene, terpineol, geraniol, thujone, camphor, viridiflorol, champhene, myrcene, caryophyllene, terpinene, carene, cirtonellol, carotol, neral, geranial and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, eucalyptol, geraniol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, caryophyllene, limonene and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, caryophyllene, limonene, eucalyptol, geraniol and combinations thereof. According to various embodiments said primary terpene comprises limonene, nerolidol, sabinene, pinene, caryophyllene, terpineol, thujone, camphor, viridiflorol, champhene, myrcene, caryophyllene, terpinene, carene, cirtonellol, carotol, neral and / or geranial. According to an embodiment, said therapeutic effect treats premenstrual syndrome (PMS), premenstrual tension, and / or premenstrual dysphoric disorder (PMDD) and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, citronellyl formate, menthol, eugenol piperine, jasmone and combinations thereof.

[00286] According to an embodiment said therapeutic effect hormonal disfunction and / or imbalance and / or fertility and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats hormonal disfunction and / or imbalance and / or fertility and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats hormonal disfunction and / or imbalance and / or fertility and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats hormonal disfunction and / or imbalance and / or fertility and said the primary terpene is selected from the group consisting of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2-en-l-ol, carotol, sabinene, neral, geranial and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, eucalyptol, geraniol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, eucalyptol, geraniol, terpineol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, eucalyptol, geraniol, pinene, caryophyllene and combinations thereof. According to various embodiments said primary terpene comprises terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2-en-l-ol, carotol, sabinene, neral and / or geranial. According to an embodiment, said therapeutic effect treats hormonal disfunction and / or imbalance and / or fertility and the product further comprises a compound selected from the group consisting of linally acetate, geranyl acetate, chamazulene, citronelly formate, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, sclareol, diosgenin, acetin, cimicifugoside and combinations thereof.

[00287] According to an embodiment said therapeutic effect treats pre-eclampsia toxemia and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats pre-eclampsia toxemia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats pre-eclampsia toxemia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats pre- eclampsia toxemia and said the primary terpene is selected from the group consisting of limonene, neral, geranial, caryophyllene, linalool, myrcene, nerolidol, fenchol, humulene, guaiol, borneol, cymene, terpinene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, myrcene, limonene and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, myrcene, limonene, caryophyllene and combinations thereof. According to various embodiments said primary terpene comprises neral, geranial, caryophyllene, nerolidol, fenchol, humulene, guaiol, borneol, cymene and / or terpinene.

[00288] According to an embodiment said therapeutic effect treats conditions and / or symptoms associated with female hormonal disfunction and / or imbalance and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats conditions and / or symptoms associated with female hormonal disfunction and / or imbalance and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats conditions and / or symptoms associated with female hormonal disfunction and / or imbalance and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats conditions and / or symptoms associated with female hormonal disfunction and / or imbalance and said the primary terpene is selected from the group consisting of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2-en-l-ol, carotol, sabinene, neral, geranial, nerolidol, terpineol, carene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of geraniol, linalool, eucalyptol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of terpineol, linalool, caryophyllene, pinene and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of geraniol, linalool, eucalyptol, caryophyllene, terpineol, pinene, limonene and combinations thereof. According to various embodiments said primary terpene comprises terpineol, geraniol, thujone, camphor, viridiflorol, borneol, champhene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, cirtonellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2- en-l-ol, carotol, sabinene, neral, geranial, nerolidol, terpineol and / or carene. According to an embodiment, said therapeutic effect treats conditions and / or symptoms associated with female hormonal disfunction and / or imbalance and the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00289] According to an embodiment said therapeutic effect treats conditions and / or symptoms associated with perimenopause and / or menopause and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats conditions and / or symptoms associated with perimenopause and / or menopause and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats conditions and / or symptoms associated with perimenopause and / or menopause and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats conditions and / or symptoms associated with perimenopause and / or menopause and said the primary terpene is selected from the group consisting of caryophyllene, caryophyllene oxide, carene, linalool, myrcene, terpinene, terpineol, citronellol, eucalyptol, nerolidol, limonene, geraniol, menthol, iso- menthone, germacrene, pinene, cardinol, neral, geranial, menth-2-en-l-ol, pulegone, cymene, fenchol, humulene, guaiol, borneol, carene, sabinene, myrtenol, camphene, nerol, farnesol, carotol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene, linalool, carene and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene, linalool, myrcene and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of nerolidol, limonene, linalool and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene, linalool, carene, nerolidol, limonene and combinations thereof. According to various embodiments said primary terpene comprises caryophyllene, caryophyllene oxide, carene, myrcene, terpinene, terpineol, citronellol, eucalyptol, nerolidol, limonene, geraniol, menthol, iso-menthone, germacrene, pinene, cardinol, neral, geranial, menth-2-en-l-ol, pulegone, cymene, fenchol, humulene, guaiol, borneol, carene, sabinene, myrtenol, camphene, nerol, farnesol and / or carotol. According to an embodiment, said therapeutic effect treats conditions and / or symptoms associated with perimenopause and / or menopause and the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

[00290] According to an embodiment said therapeutic effect treats pain and / or cramps and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats pain and / or cramps and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats pain and / or cramps and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats pain and / or cramps and said the primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso-menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2-en-l-ol, guaiol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, eucalyptol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, eucalyptol, myrcene and combinations thereof. According to various embodiments said primary terpene comprises myrcene, caryophyllene, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, camphene, terpinene, borneol, camphor, menthone, iso-menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2-en-l-ol and / or guaiol.

[00291] According to an embodiment said therapeutic effect treats female urogenital and / or reproductive system infections and / or disorders and said product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats female urogenital and / or reproductive system infections and / or disorders and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats female urogenital and / or reproductive system infections and / or disorders and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats female urogenital and / or reproductive system infections and / or disorders and said the primary terpene is selected from the group consisting of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l-ol, borneol, eucalyptol, myrtenol, cymene, caryophyllene oxide, ocimene, nerolidol, camphor, sabinene, thujone, camphor, viridiflorol, menthol, iso-menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, thujone and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, pinene, caryophyllene oxide and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of geraniol, linalool, pinene, caryophyllene oxide and combinations thereof. According to various embodiments said primary terpene comprises myrcene, humulene, caryophyllene, terpineol, geraniol, germacrene, cirtonellol, limonene, myrcene, terpinene, menth-2-en-l-ol, borneol, eucalyptol, myrtenol, cymene, ocimene, nerolidol, camphor, sabinene, thujone, camphor, viridiflorol, menthol, iso-menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene and / or thujone.

[00292] According to an embodiment, the product comprises an additive selected from the group consisting of antioxidants, emulsifiers and texturizers vegetable oils, plant extracts, honey, pharmaceutical excipients, sucrose, glucose and fructose, pharmaceutical excipients and combinations thereof. According to an embodiment, the product comprises a surfactant selected from the group consisting of phospholipids, glycerides, glycolipids and combinations thereof. According to an embodiment, the product further comprises a food-approved texturizer. According to an embodiment, the product further comprises at least 10ppm ethanol. According to an embodiment, the product further comprises at least one of vitamin C, vitamin E, polyunsaturated fatty acids, beeswax and coconut oil. According to an embodiment, the product further comprises a sweetener. According to an embodiment, the product further comprises omega 3 fatty acid. According to an embodiment, the product further comprises omega 6 fatty acid. According to an embodiment, the product further comprises omega 3 fatty acid. According to an embodiment, the product further comprises curcumin.

[00293] According to an embodiment, the terpene-enriched cannabinoid product of improved therapeutic effect is a human medication. According to an embodiment, the terpene- enriched cannabinoid product of improved therapeutic effect is a veterinary medication.

[00294] According to an embodiment, the shelf life of the product is at least 6 months or at least a year. According to an embodiment, primary terpene degradation in the product is less than 20% per year.

[00295] According to an embodiment, further provided is a product selected from the group consisting of tablets, gel capsules, medical patches, topicals, creams, varnishes, sublingual oils, sprays, edibles, suppositories, tampons, rectal candle, cigarette, vaporizer liquid nasal preparation, preparations containing micro and nano-emulsions, preparations containing micro and nano-particles and combinations thereof, containing the product. According to an embodiment, further provided is a product comprising tablets containing the product. According to an embodiment, further provided is a product comprising gel capsules containing the product. According to an embodiment, further provided is a product comprising medical patches containing the product. According to an embodiment, further provided is a product comprising topicals containing the product. According to an embodiment, further provided is a product comprising creams containing the product. According to an embodiment, further provided is a product comprising varnishes containing the product. According to an embodiment, further provided is a product comprising sublingual oils containing the product. According to an embodiment, further provided is a product comprising edibles containing the product. According to an embodiment, further provided is a product comprising tampons containing the product. According to an embodiment, further provided is a product comprising rectal candles containing the product. According to an embodiment, further provided is a product comprising cigarettes containing the product. According to an embodiment, further provided is a product comprising vaporizer liquids containing the product.

[00296] According to an embodiment, further provided is a commercial product comprising two products according to the present invention, which two products differ in the content of the primary terpene. According to an embodiment, further provided is a commercial product comprising two products according to the present invention, which two products comprise different primary terpenes.

[00297] According to an embodiment, further provided is a method for producing the product comprising providing at least one cannabinoid and blending it with a primary terpene.

[00298] According to an embodiment, the method includes extracting cannabis plant material to form an extract. According to an embodiment the extracting comprises steam distillation. According to an embodiment, the method further comprises removing terpenes from the extract prior to the blending. According to an embodiment, the extracting comprises contacting with an extractant to form an extract, which extract comprises at least one cannabinoid and the extractant; and optionally removing at least a fraction of the extractant from the extract. According to an embodiment, the extractant comprises at least one of ethanol, a liquefied gas, such as butane, butene or dimethyl-ether, liquefied CO2, near-critical CO2 supercritical CO2 and combinations thereof. According to an embodiment, extracting comprises contacting the cannabis plant material with an extractant to form an extract, and the extractant comprises at least one terpene. According to an embodiment, the extractant comprises the primary terpene.

[00299] According to an embodiment, the method further comprises at least partially decarboxylating the cannabinoid. According to an embodiment the decarboxylating is conducted at a temperature greater than 100°C. According to an embodiment the decarboxylating is conducted prior to extracting. According to an embodiment the decarboxylating is conducted on the extract prior to the blending with the primary terpene. According to an embodiment, a fraction of the extract is decarboxylated, and the decarboxylated fraction is blended with another fraction, which was not decarboxylated.

[00300] According to an embodiment, the method further comprises extracting a plant material, whereby the primary terpene is produced. According to an embodiment, the plant material is selected from the group including cannabis, lemons, oranges, hops, lavender, pine needles, Echinacea, tea, clover, capsicum, eucalyptus, geranium and mint.

[00301] According to an embodiment, the method comprises synthesizing at least one cannabinoid and blending the synthesized cannabinoid with the primary terpene.

[00302] According to an embodiment, the method further comprises blending cannabis plant material with the primary terpene. According to an embodiment, the cannabis plant material comprises a cannabis bud. According to an embodiment, the blending cannabis plant material with the primary terpene comprises spraying the cannabis plant material with the primary terpene, optionally in a solvent. According to an embodiment, the blending cannabis plant material with the primary terpene comprises combining the cannabis plant material with a substrate comprising the primary terpene. According to an embodiment, the substrate is a plant material sprayed with the primary terpene. According to an embodiment, the substrate is a cigarette paper sprayed with the primary terpene.

[00303] According to an embodiment, further provided is a method for producing the product comprising extracting cannabis plant material to form an extract, wherein the extracting forms at least two extract fractions, a cannabinoid-enriched extract and a terpene-enriched extract. As used herein, the term "cannabinoid-enriched extract" refers to an extract wherein cannabinoid to terpenes weight / weight ratio is greater than that in the plant material. As used herein, the term "terpene-enriched extract" refers to an extract wherein cannabinoid to terpenes weight / weight ratio is smaller than that in the plant material. According to an embodiment, the method comprises dividing the cannabinoid-enriched extract into at least two fractions and mixing at least one fraction with at least part of the terpene-enriched extract to form a terpene- enriched product, wherein terpenes to cannabinoid weight / weight ratio is greater than that ratio in the cannabis plant material. According to an embodiment the ratio is 1.5 times greater than that in the cannabis plant material, 2 times greater, 2.5 times greater, 3 times greater, 4 times greater, 5times greater, 6 times greater, 7 times greater, 8 times greater, or 10 times greater. According to an embodiment, the terpene-enriched product is further mixed with at least one terpene.

[00304] According to an embodiment, further provided is a method for reaching, achieving and / or gaining a therapeutic effect in treating conditions and / or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and / or disorders, menstrual cycle, hormonal deficiency and / or hormonal imbalance comprising administering to a subject in need a therapeutically effective amount of a product comprising (i) at least one cannabinoid in a specific amount, (ii) a primary terpene in a specific amount, (iii) at least 5% by weight of a non-cannabinoid, non-terpene, carrier; (iv) optionally at least three secondary terpenes; and (v) optionally at least one phytoestrogen, optionally combined with at least one herbal extract. According to an embodiment, the product is selected from the group consisting of cigarettes, vaporizer plant material, vaporizer liquid, extract, tablets, gel capsules, suppositories, tampons, rectal candle, cigarette, vaporizer liquid nasal preparation, preparations containing micro and nano-emulsions, preparations containing micro and nano-particles and combinations thereof. According to an embodiment, the daily dose of the product comprises about 1 milligram cannabinoid to about 300 milligram, about 2 milligram cannabinoid to about 200 milligram or about 3 milligram cannabinoid to about 100 milligram. According to another embodiment, the daily dose of the product comprises about 0.5 milligram cannabinoid per kilogram body weight to about 30 milligram cannabinoid per kilogram body weight.

[00305] According to an embodiment, the administered product comprises at least two cannabinoids, at least three, at least four or at least five. According to an embodiment, the content of each cannabinoid in the product is at least 10 parts per million (ppm). According to an embodiment, the cannabinoids are selected from the group consisting THC, CBD, CBC, CBN, CBL, THCV, CBDV and their non-decarboxylated form thereof.

[00306] According to an embodiment, the administered product comprises at least 5% by weight carrier, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35% or at least 40% by weight. Any compound other than cannabinoids and terpenes is a suitable carrier. According to an embodiment, the carrier is selected from the group consisting of vegetable oils, e.g. coconut oil, olive oil or sesame oil, pharmaceutical excipients, honey, bees wax, cellulose and combinations thereof.

[00307] According to an embodiment, the administered product comprises at least one phytoestrogen. According to an embodiment, the product comprises at least two, at least three, at least four, or at least five phytoestrogens.

[00308] According to an embodiment, the administered product comprises a primary terpene and optionally at least three secondary terpenes, at least four or at least five. According to an embodiment, the primary terpene forms at least 20% by weight of the total amount of terpenes in the product, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80%. According to an embodiment, the product comprises multiple (e.g. two or three) terpenes, each one of which forms at least 20% by weight of the total amount of terpenes in the product and each one of these terpenes is considered a primary terpene. According to an embodiment, the content of the primary terpene in the product is at least 2 times greater than that of any secondary terpene, at least 4, at least 6, at least 8, at least 10, at least 15, at least 20, at least 25, or at least 30 times greater.

[00309] According to an embodiment, the administered product is combines with at least one herbal extract, at least two, at least three, at least four, or at least five herbal extracts.

[00310] According to an embodiment, the administered product comprises less than 5% by weight glycol, less than 4%, less than 3%, less than 2%, or less than 1% by weight.

[00311] According to an embodiment, the administered product comprises less than 20% by weight water, less than 15% by weight, less than 14%, less than 13%, less than 12%, less than 11% or less than 10% by weight.

[00312] According to a related embodiment, the administered product comprises chlorophyll. According to an embodiment, the product comprises at least 0.5% by weight chlorophyll, at least 1%, at least 5%, at least 10%, at least 15%, at least 20% chlorophyll. According to an embodiment, the administered product comprises at least one flavonoid. According to an embodiment, the product comprises at least two, at least three, at least four, or at least five flavonoids. According to an embodiment, the administered product comprises at least one of isoflavones, coumestans, prenylflavonoids, lignans and saponins. According to an embodiment, the product comprises isoflavones. According to an embodiment, the product comprises coursetans. According to an embodiment, the product comprises prenylflavonoids. According to an embodiment, the product comprises lignans. According to an embodiment, the product comprises saponins. According to an embodiment, the product comprises at least one of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin and / or cimicifugoside. According to an embodiment, the product comprises biochanin A. According to an embodiment, the product comprises formonenetin. According to an embodiment, the product comprises genistein. According to an embodiment, the product comprises daidzein. According to an embodiment, the product comprises glycitein. According to an embodiment, the product comprises prenylnaringenin. According to an embodiment, the product comprises diosgenin. According to an embodiment, the product comprises acetin. According to an embodiment, the product comprises cimicifugoside.

[00313] According to an embodiment, the non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in the product is about 0.1 to about 1.0. According to an embodiment said non-cannabinoid, non-terpene, carrier comprises at least 5% by weight cellulose, at least 6%, at least 8%, at least 10%, at least 15%, or at least 20%. According to an embodiment, the ratio is greater than 0.1, greater than 0.15, greater than 0.2, greater than 0.25, greater than 0.3, greater than 0.35, greater than 0.4, greater than 0.45, greater than 0.5, greater than 0.55, greater than 0.6, greater than 0.65, greater than 0.7, greater than 0.75, greater than 0.8, greater than 0.85, greater than 0.9, greater than 0.95, greater than 1, greater than 1.2, greater than 1.5, greater than 2.0, greater than 3 or greater than 5. According to an embodiment, the ratio is less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2 or less than 0.15. According to an embodiment, the product comprising more than 5% cellulose is selected from the group consisting of cannabis plant material, e.g. cannabis buds or cannabis trim, ground forms thereof, plant material preparation for vaporizers and cannabis cigarette.

[00314] According to an embodiment, the non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight / weight ratio in the product is about 0.05 to about 1.0. According to an embodiment said non-cannabinoid, non- terpene, carrier comprises less than 5% by weight cellulose, less than 4%, less than 3%, less than 2%, or less than 1% cellulose. According to an embodiment, the ratio is greater than 0.1, greater than 0.15, greater than 0.2, greater than 0.25, greater than 0.3, greater than 0.35, greater than 0.4, greater than 0.45, greater than 0.5, greater than 0.55, greater than 0.6, greater than 0.65, greater than 0.7, greater than 0.75, greater than 0.8, greater than 0.85, greater than 0.9, greater than 0.95, greater than 1, greater than 1.2, greater than 1.5, greater than 2.0, greater than 3 or greater than 5. According to an embodiment, the ratio is less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2, less than 0.15 or less than 0.1. According to an embodiment, the product comprising less than 5% cellulose is selected from the group consisting of cannabis trichomes, cannabis extracts and products thereof, such as tablets, gel capsules, medical patches, vaporizer liquids and suppositories, tampons, rectal candle, cigarette, vaporizer liquid nasal preparartion, preparations containing micro and nano- emulsions, preparations containing micro and nano-particles and combinations thereof.

[00315] According to an embodiment, the conditions and / or symptoms associated with menopause are selected from the group consisting of hot flashes, facial flushing, night sweat, osteoporosis, fatigue, irritability, insomnia and / or sleep disorder, difficulty in concentration, depression, memory loss, brain fog, headache, migraine, anxiety, nervousness, restless, stress, mood swing, affect disorder, general discomfort, muscle tension, myalgia, intermittent dizziness, paresthesia, indigestion, digestive problems, intestinal disorders, abdominal pain, irritability, palpitations, tachycardia, nausea, constipation, diarrhea, arthralgia and / or arthritis, dysmenorrheal, pelvic pain, spasms, cramps, labor contraction, endometriosis Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia, premenstrual syndrome (PMS), premenstrual tension, premenstrual dysphoric disorder (PMDD), cold hands and feet, weight gain, mental awareness problems, sexual pain disorder, dyspareunia, breast pain and / or mastalgia, menopausal skin, inflammation, oxidative stress, cardiovascular disease, loss of pelvic muscle tone, urinary incontinence, lower urinary tract disorders, vaginal dryness, women urogenital and / or reproductive system infection, fibroid, myomas and / or cysts in the female genital system, human papillomavirus (HPV), Uterine Fibroid, cystitis, urethritis, pyelonephritis, women hormonal dysfunction and / or imbalance, irregular periods, pre-eclampsia toxemia, reduced libido, reduced sexual dysfunction, hair loss and / or thinning, age-related winkles, stretch marks, brittle nails, gam disorders, irregular body odor, conditions and / or symptoms induced by estrogen deficiency and combinations thereof.

[00316] According to an embodiment, the administered product additionally contains an additive selected from the group consisting of antioxidants, emulsifiers and texturizers vegetable oils, plant extracts, honey, sucrose, glucose and fructose, pharmaceutical excipients and combinations thereof.

[00317] According to an embodiment, the non-cannabinoid, non-terpene, carrier comprises cellulose, and the administered product comprises (a) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 5% by weight; (b) cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 5% by weight; (c) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 2.5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 2.5% by weight; or (d) at least one of cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and cannabicyclol (CBL), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), and non-decarboxylated form thereof in a concentration of at least 0.5% by weight; and (i) the primary terpene forms at least 40% by weight of the total terpene content, and (ii) the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1- ol, farensol, carotol, myrtenol and combinations thereof.

[00318] According to a related embodiment said non-cannabinoid, non-terpene, carrier comprises at least 5% by weight cellulose, at least 6%, at least 8%, at least 10%, at least 15%, or at least 20%.

[00319] According to a related embodiment said tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) is in a total concentration of at least 4% by weight, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18%, or at least 20% by weight.

[00320] According to a related embodiment said cannabidiol (CBD) and / or cannabidiolic acid (CBDa) is in a total concentration of at least 4% by weight, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20% by weight.

[00321] According to a related embodiment, said administered product comprises tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 2.5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 2.5% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 3% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 3% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 4% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 4% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 5% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 8% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 8% by weight; tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 10% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 10% by weight.

[00322] According to a related embodiment, said administered product comprises cannabigerol (CBG) and / or cannabigerol acid (CBGa) in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises cannabinol (CBN) and / or cannabinol acid (CBNa) in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises cannabichromene (CBC) and / or cannabichromenic acid (CBCa) in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises cannabicyclol (CBL) and / or cannabicyclol acid (CBLa) in a total concentration at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises tetrahydrocannabivarin (THCV), and / or tetrahydrocannabivarin acid (THCVA) in a total concentration at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight. According to a related embodiment, said product comprises cannabidivarin (CBDV) and / or cannabigerovarin acid (CBGVA) in a total concentration at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, or at least 5% by weight.

[00323] According to a related embodiment, said primary terpene forms at least 20% by weight of the total terpene content, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% by weight of the total terpene content. According to a related embodiment, said primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof. According to a related embodiment, said product comprises a dried cannabis plant material. According to a related embodiment, said product comprises ground cannabis plant material, is a vaporizer cannabis filling material or is a cannabis cigarette.

[00324] According to an embodiment, the administered product comprises (a) at least one cannabinoid from the group consisting of THC, CBD, CBG, CBC, CBN, CBL, THCV, CBDV and their non-decarboxylated form thereof; (b) a non-cannabinoid, non-terpene carrier, comprising less than 5% by weight cellulose; (c) a primary terpene, forming at least 40% by weight of the total terpene content, wherein the primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[00325] According to a related embodiment said THC and / or THCa is in a total concentration of at least 1% by weight, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00326] According to a related embodiment said CBD and / or CBDa is in a total concentration of at least 1% by weight, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00327] According to a related embodiment said CBG and / or CBGa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00328] According to a related embodiment said CBC and / or CBCa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00329] According to a related embodiment said CBN and / or CBNa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00330] According to a related embodiment said CBL and / or CBLa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00331] According to a related embodiment said THCV and / or THCVa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00332] According to a related embodiment said CBDV and / or CBDVa is in a total concentration of at least 0.1% by weight, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18% or at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% by weight.

[00333] According to a related embodiment said non-cannabinoid non-terpene carrier comprises less than 5% by weight cellulose, less than 4%, less than 3%, less than 2%, or less than 1%, or less than 0.5% by weight cellulose.

[00334] According to a related embodiment, said primary terpene forms at least 20% by weight of the total terpene content, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% by weight of the total terpene content. According to a related embodiment, said primary terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof. According to an embodiment, said administered product is liquid. According to an embodiment, said administered product is selected from the group consisting of vaporizer cannabis filling liquid, cannabis tablets, cannabis suppositories, tampons, rectal candle, cigarette, vaporizer liquid nasal preparation, preparations containing micro and nano-emulsions, preparations containing micro and nano-particles, cannabis gel capsules, cannabis candies, cannabis drinks and cannabis baked products.

[00335] According to an embodiment, the primary terpene of the administered product is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

[00336] According to an embodiment, the product results in an increased therapeutic effect compared with that of a product comprising the same cannabinoids amounts and a smaller amount of the primary terpene, e.g. one half of that amount. According to various embodiment, the increased therapeutic effect has various forms, e.g. a shorter onset time, increased magnitude, extended duration, reduced dosages, reduced secondary adverse symptoms, reduced frequency of conditions and / or symptoms, reduced severity of conditions and / or symptoms, reduced consumption of other drugs and combinations thereof. According to an embodiment, the increased therapeutic effect comprises a shorter onset time, or differently put an earlier effect, which is important particularly in cases of sublingual and topical delivery and in cases where a rapid effect is desired, as in treating pain. According to an embodiment, the increased therapeutic effect comprises extended duration of the therapeutic effect, for example an extended time of pain relief. According to an embodiment, the increased therapeutic effect comprises increased magnitude of the therapeutic effect, enabling achieving a desired therapeutic effect on administering smaller doses of cannabinoids, saving thereby on cost. According to an embodiment, the increased therapeutic effect comprises using smaller doses of cannabinoids and still achieving at least the same beneficial result. According to an embodiment, the increased therapeutic effect comprises reduction of secondary adverse symptoms, e.g. adverse symptoms of the main illness, of ones of another illness and / or ones related to administered the product or other drugs. According to an embodiment, the increased therapeutic effect comprises reduced frequency of the conditions and / or symptoms. According to an embodiment, the increased therapeutic effect comprises reduced severity of the conditions and / or symptoms.

[00337] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect, as measured by methods known in the art, is at least 20% shorter than that of administering a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% shorter. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect is at least 20% shorter than that of administering a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% short. Shorter onset time, or differently put an earlier effect, is important particularly in cases of sublingual and topical delivery and in cases where a rapid effect is desired, as in treating pain.

[00338] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect is at least 20% longer than that of administering a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% longer. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the onset time of the therapeutic effect is at least 20% longer than that of administering a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% longer. According to an embodiment, products of delayed onset time are used in combination with shorter onset time to reach a sustained release effect.

[00339] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the magnitude of the therapeutic effect, as measured by methods known in the art, is at least 20% greater compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% greater. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the magnitude of the therapeutic effect is at least 20% greater than that of administering a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% greater. Without wishing to be limited by any particular theory, such increased magnitude of the therapeutic effect may indicate increased bioavailability. Such increased magnitude enables achieving a desired therapeutic effect on administering smaller doses of cannabinoids, saving thereby on cost.

[00340] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the duration of the therapeutic effect, as measured by methods known in the art, is at least 20% longer compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% longer. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the duration of the therapeutic effect is at least 20% longer than that of administering a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60% at least 70%, at least 80%, at least 90% or at least 100% longer.

[00341] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the frequency of the conditions and / or symptoms, as measured by methods known in the art, is at least 20% smaller compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50% at least 60%.at least 70%, at least 80%, or at least 90% smaller. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the frequency of the conditions and / or symptoms, as measured by methods known in the art, is at least 20% smaller than that of administering a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60% at least 70%, at least 80%, at least 90% or at least 100% longer.

[00342] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the severity of the conditions and / or symptoms, as measured by methods known in the art, is at least 20% smaller compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50% at least 60%, at least 70%, at least 80%, or at least 90% smaller. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the severity of the conditions and / or symptoms, as measured by methods known in the art, is at least 20% smaller than that of administering a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% smaller.

[00343] According to an embodiment, the primary terpene and the cannabinoids are present in specific amounts, and the consumption of other drugs is reduced by at least 20% compared with that of administering a product comprising the same cannabinoids amounts and one half the amount of said primary terpene, reduced by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 80%, or by at least 90%. According to an embodiment, the primary terpene, secondary terpenes and the cannabinoids are present in specific amounts, and the consumption of other drugs, as measured by methods known in the art, is reduced by at least 20% compared with administering a product comprising the same cannabinoids amounts, same secondary terpene amounts and one half the amount of the primary terpene, reduced by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 80%, or by at least 90%.

[00344] According to an embodiment said therapeutic effect treats osteoporosis and said administered product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats osteoporosis and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats osteoporosis and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats osteoporosis and said the primary terpene is selected from the group consisting of caryophyllene, caryophyllene oxide, carene, eucalyptol, sabinene, pinene, limonene, borneol, thymol, camphor and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of caryophyllene, carene, borneol and combinations thereof. According to various embodiments said primary terpene comprises caryophyllene oxide, eucalyptol, sabinene, pinene, limonene, thymol and / or camphor. According to an embodiment, said therapeutic effect treats osteoporosis and the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, said therapeutic effect treats osteoporosis and the product further comprises an herbal extract selected from the group consisting of angelica sinensis, cimicifuga (Actaea) racemosa, dioscorea villosa, trifolium pratense and combinations thereof.

[00345] According to an embodiment said therapeutic effect treats sleep disorder and / or insomnia and said administered product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats sleep disorder and / or insomnia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats sleep disorder and / or insomnia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats sleep disorder and / or insomnia and said the primary terpene is selected from the group consisting of linalool, caryophyllene, myrcene, terpineol, terpinene, citronellol, eucalyptol, nerolidol, sabinene, pinene, limonene, borneol, fenchol, bisabolol humulene, phytol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, caryophyllene, myrcene and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of linalool, nerolidol, myrcene and combinations thereof. According to various embodiments said primary terpene comprises terpineol, terpinene, citronellol, eucalyptol, nerolidol, sabinene, pinene, limonene, borneol, fenchol, bisabolol, phytol and / or humulene. According to an embodiment, said therapeutic effect treats sleep disorder and / or insomnia and the product further comprises a compound selected from the group consisting of linally acetate, chamazulene, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, said therapeutic effect treats sleep disorder and / or insomnia and the product further comprises an herbal extract selected from the group consisting of avena sativa, cimicifuga (Actaea) racemosa, humulus lupulus, hypericum perforatum, lavendula officinalis, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof. According to an embodiment, the product includes caryophyllene, and caryophyllene forms less than 5% by weight of the total terpene content.

[00346] According to an embodiment said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and said administered product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and said the primary terpene is selected from the group consisting of limonene, linalool, terpineol, citronellol, eucalyptol, caryophyllene, geraniol, menthol, iso-menthone, germacrene, pinene, citronellol, cardinol, neral, geranial, myrcene, terpinene, menth-2-en-l-ol, humulene, bisabolol, borneol, fenchol, nerolidol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, eucalyptol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, caryophyllene, bisabolol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of limonene, linalool, pinene, humulene and combinations thereof. According to various embodiments said primary terpene comprises terpineol, citronellol, caryophyllene, geraniol, menthol, iso-menthone, germacrene, pinene, citronellol, cardinol, neral, geranial, myrcene, terpinene, menth-2-en-l-ol, humulene, bisabolol, borneol, nerolidol or fenchol. According to an embodiment, said therapeutic effect treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and the product further comprises a compound selected from the group consisting of linalyl acetate, geranyl acetate, menthol, piperine, eugenol, citronellyl formate, jasmone, benzy acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, said therapeutic effect treats treats anxiety, irritability, nervousness, restless, stress, depression, mood swing and / or affect disorder and the product further comprises an herbal extract selected from the group consisting of avena sativa, bacopa monnieri, centella (hydrocotyl) asiatica, humulus lupulus, hypericum perforatum, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof. According to an embodiment, the product includes pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene, and pinene, terpineol, bisabolol, caryophyllene, myrcene and / or limonene forms less than 5% by weight of the total terpene content.

[00347] According to an embodiment said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and said administered product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and said the primary terpene is selected from the group consisting of eucalyptol, pinene, carene, limonene, pulegone, terpineol, cymene, linalool, caryophyllene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of eucalyptol, pinene, limonene and combinations thereof. According to various embodiments said primary terpene comprises carene, pulegone, terpineol, linalool, caryophyllene and / or cymene According to an embodiment, said therapeutic effect treats difficulty in concentrating, brain fog and / or memory loss and the product further comprises a compound selected from the group consisting of biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, said therapeutic effect treats brain fog and / or memory loss and the product further comprises an herbal extract selected from the group consisting of asphalentum ponjabianum - mumio, bacopa monnieri, centella (hydrocotyl) asiatica, eleutherococcus senticosus, ginkgo biloba, lepidium meyenii, lycium barbarum, paullinia cupana, rhodiola rosea and combinations thereof.

[00348] According to an embodiment said therapeutic effect treats general discomfort and said administered product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats general discomfort and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats general discomfort and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats general discomfort and said the primary terpene is selected from the group consisting of limonene, linalool humulene, terpinene, borneol, caryophyllene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, humulene, terpinene and combinations thereof. According to various embodiments said primary terpene comprises limonene, borneol and / or caryophyllene. According to an embodiment, the product includes myrcene, pinene and / or bisabolol, and myrcene, pinene and / or bisabolol forms less than 5% by weight of the total terpene content.

[00349] According to an embodiment said therapeutic effect treats muscle tension and / or myalgia and said administered product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats muscle tension and / or myalgia and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats muscle tension and / or myalgia and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats muscle tension and / or myalgia and said the primary terpene is selected from the group consisting of myrcene, pinene, nerolidol, linalool, humulene, caryophyllene, limonene, bisabolol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of myrcene, pinene, nerolidol and combinations thereof. According to an embodiment, the primary terpene is selected from the group consisting of myrcene, pinene, nerolidol, linalool, humulene and combinations thereof. According to various embodiments said primary terpene comprises linalool, humulene, caryophyllene, limonene and / or bisabolol... According to an embodiment, said therapeutic effect treats muscle tension and / or myalgia and the product further comprises an herbal extract selected from the group consisting of boswellia spp, salix alba, valeriana edulis, viburnum opulus, chamaemelum and combinations thereof.

[00350] According to an embodiment said therapeutic effect treats fatigue and / or intermittent dizziness and said administered product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats fatigue and / or intermittent dizziness and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats fatigue and / or intermittent dizziness and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats fatigue and / or intermittent dizziness and said the primary terpene is selected from the group consisting of pinene, limonene, terpinene, eucalyptol, myrcene, terpineol, linalool, caryophyllene and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of pinene, limonene, eucalyptol and combinations thereof. According to various embodiments said primary terpene comprises terpinene, myrcene and / or caryophyllene. According to an embodiment, said therapeutic effect treats fatigue and / or intermittent dizziness and the product further comprises an herbal extract selected from the group consisting of eleutherococcus senticosus, ganoderma lucidum, grifola frondosa, lentinula edodes, lepidium meyenii, panax ginseng, rhodiola rosea and combinations thereof.

[00351] According to an embodiment said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks and said administered product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats menopausal skin, itchy skin, age- related wrinkles and / or stretch marks and said the primary terpene is selected from the group consisting of linalool limonene, nerolidol, pinene terpineol, myrcene, geraniol, nerol, citronellol, farnesol, carotol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of linalool, terpineol, geraniol and combinations thereof. According to various embodiments said primary terpene comprises limonene, nerolidol, pinene myrcene, nerol, citronellol, farnesol and / or carotol. According to an embodiment, said therapeutic effect treats menopausal skin, itchy skin, age- related wrinkles and / or stretch marks and the product further comprises a compound selected from the group consisting of linally acetate, citronelly formate, eugenol, benzy acetate, benzyl alcohol, biochanin A, formonenetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. According to an embodiment, said therapeutic effect treats menopausal skin, itchy skin, age-related wrinkles and / or stretch marks and the product further comprises an herbal extract selected from the group consisting of glycyrrhiza glabra, plantago spp, symphytum officinalis, trifolium pratense, trigonella foenum graecum, ulmus rubra\fulva, verbascum thapsus and combinations thereof.

[00352] According to an embodiment said therapeutic effect treats headache and / or migraine and said administered product comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats headache and / or migraine and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats headache and / or migraine and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats headache and / or migraine and said the primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, limonene, nerolidol, fenchol, humulene, guaiol, borneol, pinene, bisabolol, terpinene, terpineol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from the group consisting of myrcene, linalool, caryophyllene and combinations thereof. According to various embodiments said primary terpene comprises eucalyptol, limonene, nerolidol, fenchol, humulene, guaiol, linalool, limonene, borneol, pinene and / or bisabolol. According to an embodiment, said therapeutic effect treats headache and / or migraine and the product further comprises an herbal extract selected from the group consisting of angelica sinensis, corydalis yanhusuo, piscidia erythrina, rosmarinus officinalis, stachys betonica, tanacetum parthenium, verbena officinalis and combinations thereof. According to an embodiment, the product includes bisabolol, terpinene, humulene and / or linalool wherein bisabolol, terpinene, humulene and / or linalool forms less than 5% by weight of the total terpene content.

[00353] According to an embodiment said therapeutic effect treats weight gain and said product administered comprises at least one of CBD, THC, CBC, CBG, CBN, CBL, THCV and CBDV. According to an embodiment said therapeutic effect treats weight gain and said product comprises CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, greater than 2, greater than 3, greater than 4 or greater than 5. According to an embodiment said therapeutic effect treats weight gain and said product comprises THC and optionally CBD at THC to CBD weight / weight ratio greater than 0.9, greater than 2, greater than 3, greater than 4 or greater than 5. According to various embodiments, said product comprises CBD, comprises THC, comprises CBC, comprises CBG, comprises CBN, comprises CBL, comprises THCV and / or comprises CBDV. According to an embodiment said therapeutic effect treats weight gain and said the primary terpene is selected from the group consisting of eucalyptol, caryophyllene, limonene, humulene, phytol and combinations thereof. According to an embodiment, the product comprises at least 2 of these terpenes, at least 3, at least 4, or at least 5 of the terpenes. According to an embodiment, the primary terpene is selected from th...

Claims

1. A product comprising (i) at least one cannabinoid selected from the group consisting of THC, CBD, CBG, CBC, CBN, CBL, THCV, CBDV and non-decarboxylated forms thereof, (ii) at least one terpene, (iii) at least 5% by weight of a non-cannabinoid, non-terpene carrier, and; (a)wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in said product is about 0.1 to about 1.0, or; (b)wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight / weight ratio in said product is about 0.05 to about 1.0, for use in treating conditions and / or symptoms in a female subject, wherein said conditions or symptoms are selected from the group consisting of perimenopause, menopause, female urogenital or reproductive system infections, female urogenital or reproductive system disorders, menstrual cycle disorders, hormonal deficiency, hormonal imbalance and combinations thereof.

2. The product of Claim 1, selected from the group consisting of tablets, gel capsules, medical patches, topicals, creams, varnishes, sublingual oils, sprays, edibles, suppositories, tampons, rectal candles, cigarettes, vaporizer liquids, nasal preparations micro and / or nano-emulsions, and micro and / or nano- particles. 3• The product of Claim 1, wherein said conditions and / or symptoms are selected from the group consisting of hot flashes, facial flushing, night sweat, osteoporosis, fatigue, irritability, insomnia and / or sleep disorder, difficulty in concentration, depression, memory loss, brain fog, headache, migraine, anxiety, nervousness, restless, stress, mood swing, affect disorder, muscle tension, myalgia, intermittent dizziness, paresthesia, indigestion, digestive problems, intestinal disorders, abdominal pain, palpitations, tachycardia, nausea, constipation, diarrhea, arthralgia and / or arthritis, dysmenorrhea, pelvic pain, spasms, cramps, labor contraction, endometriosis, Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, metrorrhagia, premenstrual syndrome (PMS), premenstrual tension, premenstrual dysphoric disorder (PMDD), cold hands and feet, weight gain, mental awareness problems, sexual pain disorder, dyspareunia, breast pain and / or mastalgia, menopausal skin, inflammation, oxidative stress, cardiovascular disease, loss of pelvic muscle tone, urinary incontinence, lower urinary tract disorders, vaginal dryness, women urogenital and / or reproductive system infection, fibroid, myomas and / or cysts in the female genital system, human papillomavirus (HPV), Uterine Fibroid, cystitis, urethritis, pyelonephritis, women hormonal dysfunction and / or imbalance, irregular periods, pre-eclampsia, toxemia, reduced libido, reduced sexual dysfunction, hair loss and / or thinning, age- related wrinkles, stretch marks, brittle nails, irregular body odor, conditions and / or symptoms induced by estrogen deficiency and combinations thereof.

4. The product of Claim 1, wherein said non-cannabinoid, non-terpene, carrier comprises cellulose, and said product comprises: (i) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 5% by weight; (ii) cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least 5% by weight; (iii) tetrahydrocannabinol (THC) and / or tetrahydrocannabinolic acid (THCa) in a total concentration of at least 2.5% by weight, and cannabidiol (CBD) and / or cannabidiolic acid (CBDa) in a total concentration of at least5. The product of Claim 1, wherein (a) the non-cannabinoid, non-terpene, carrier comprises less than 5% by weight cellulose; (b) each said at least one terpene forms at least 40% by weight of the total terpene content, and; (c) said at least one terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso- menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

6. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, borneol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, amyrin, thujone, citronellol, pulegone, cycloartenol, cymene, sabinene, carene, terpinene, fenchol, isopulegol, guaiol, phellandrene, eudesmol, ocimene, cardinol, elemene, friedelin, carvacrol, eugenol, camphor, menthol, iso-menthone, neral, gerial, viridiflorol, germacrene, thymol, Menth-2-en-1-ol, farensol, carotol, myrtenol and combinations thereof.

7. The product of Claim 1, comprising less than 5% by weight glycol.

8. The product of Claim 1, comprising less than 20% by weight water.

9. The product of Claim 1, further comprising chlorophyll.

10. The product of Claim 1, further comprising at least one flavonoid.

11. The product of Claim 1, further comprising at least one of isoflavones, coumestans, prenylflavonoids, lignans and saponins.

12. The product of Claim 1, further comprising at least one of biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin and cimicifugoside.

13. The product of Claim 1, comprising CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, wherein said at least one terpene is selected from the group consisting of caryophyllene, caryophyllene oxide, carene, eucalyptol, sabinene, pinene, limonene, borneol, thymol, camphor and combinations thereof, and wherein said condition and / or symptom comprises osteoporosis.

14. The product of Claim 13, further comprising a compound selected from the group consisting of biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

15. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of linalool, caryophyllene, myrcene, terpineol, terpinene, citronellol, eucalyptol, nerolidol, sabinene, pinene, limonene, borneol, fenchol, bisabolol, humulene, phytol and combinations thereof, and wherein said condition and / or symptom comprises sleep disorder and / or insomnia.

16. The product of Claim 15, wherein said at least one terpene includes terpineol, citronellol and / or linalool.

17. The product of Claim 15, further comprising a compound selected from the group consisting of linally acetate, chamazulene, biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

18. The product of Claim 15, wherein said at least one terpene comprises caryophyllene, wherein caryophyllene forms less than 5% by weight of the total terpene content.

19. The product of Claim 1, comprising CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, wherein said at least one terpene is selected from the group consisting of limonene, linalool, terpineol, citronellol, eucalyptol, caryophyllene, geraniol, menthol, iso-menthone, germacrene, pinene, citronellol, cardinol, neral, geranial, myrcene, terpinene, menth-2-en-l- ol, humulene, bisabolol, borneol, fenchol, nerolidol and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of anxiety, irritability, nervousness, restless, stress, depression, mood swing and affect disorder.

20. The product of Claim 19, wherein said at least one terpene is selected from the group consisting of terpineol, citronellol and linalool.

21. The product of Claim 19, further comprising a compound selected from the group consisting of linally acetate, geranyl acetate, menthol, piperine, eugenol, citronellyl formate, jasmone, benzyl acetate, benzyl alcohol, biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

22. The product of Claim 19, wherein said at least one terpene includes at least one terpene selected from the group consisting of pinene, terpineol, bisabolol, caryophyllene, myrcene and limonene, at a total concentration of less than 5% by weight of the total terpene content.

23. The product of Claim 1, comprising CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, wherein said at least one terpene is selected from the group consisting of eucalyptol, pinene, carene, limonene, pulegone, terpineol, cymene, linalool, caryophyllene and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of difficulty in concentrating, brain fog and memory loss.

24. The product of Claim 23, further comprising a compound selected from the group consisting of biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

25. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of myrcene, pinene, nerolidol, linalool, humulene, caryophyllene, limonene, bisabolol and combinations thereof, and wherein said condition and / or symptom comprises muscle tension and / or myalgia.

26. The product of Claim 1, comprising CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, wherein said at least one terpene is selected from the group consisting of pinene, limonene, terpinene, eucalyptol, myrcene, terpineol, linalool, caryophyllene and combinations thereof, and wherein said condition and / or symptom comprises fatigue and / or intermittent dizziness.

27. The product of Claim 1, comprising CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, wherein said at least one terpene is selected from the group consisting of linalool, limonene, nerolidol, pinene, terpineol, myrcene, geraniol, nerol, citronellol, farnesol, carotol and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of menopausal skin, itchy skin, age-related wrinkles and stretch marks.

28. The product of Claim 27, further comprising a compound selected from the group consisting of linally acetate, citronelly formate, eugenol, benzyl acetate, benzyl alcohol, biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

29. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, limonene, nerolidol, fenchol, humulene, guaiol, borneol, pinene, bisabolol, terpinene, terpineol and combinations thereof, and wherein said condition and / or symptom comprises headache and / or migraine.

30. The product of Claim 29, including at least one terpene selected from the group consisting of bisabolol, terpinene, humulene and linalool at a total concentration of less than 5% by weight of the total terpene content.

31. The product of Claim 1, comprising CBD and optionally THC at CBD to THC weight / weight ratio greater than 1, wherein said at least one terpene is selected from the group consisting of eucalyptol, caryophyllene, limonene, humulene, phytol and combinations thereof, and wherein said condition and / or symptom comprises weight gain.

32. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of limonene, cymene, terpinene, caryophyllene, citronellol, sabinene, myrcene, linalool, germacrene, geraniol, pinene, terpineol and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of digestive problems, intestinal disorders, abdominal pain, nausea, constipation and diarrhea.

33. The product of Claim 32, further comprising piperine.

34. The product of Claim 32, including at least one terpene selected from the group consisting of pinene, limonene and terpineol, at a total concentration of less than 5% by weight of the total terpene content. 35· The product of Claim 1, wherein said at least one terpene is selected from the group consisting of pinene, limonene, caryophyllene, myrcene, linalool, geraniol, eucalyptol, terpineol, sabinene and combinations thereof, and wherein said condition and / or symptom comprises breast pain and / or Mastalgia.

36. The product of Claim 35, further comprising a compound selected from the group consisting of biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. 37• The product of Claim 1, wherein said at least one terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, limonene, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso- menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2-en-l-ol and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of dysmenorrhea, pelvic pain, spasms, cramps, labor contraction and endometriosis.

38. The product of Claim 37, further comprising a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, methyl-eugenol, menthol, eugenyl acetate, piperine, chamazulene, citronllyl formate, benzyl acetate, benzyl alcohol, biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

39. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of myrcene, linalool, guaiol, caryophyllene, eucalyptol, pinene, nerolidol, sabinene, limonene, terpinene, menth-2-en-l-ol, geraniol, guaiol, humulene, bisabolol, borneol, fenchol, terpineol and combinations thereof, and wherein said condition and / or symptom comprises arthralgia and / or arthritis.

40. The product of Claim 39, further comprising a compound selected from the group consisting of linalyl acetate, geranyl acetate, eugenol, methyl-eugenol, menthol, eugenyl acetate, piperine and combinations thereof.

41. The product of Claim 39, including at least one terpene selected from the group consisting of humulene, pinene, bisabolol, borneol, fenchol, guaiol, linalool, terpineol, terpinene and caryophyllene, at a total concentration of less than 5% by weight of the total terpene content.

42. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of caryophyllene, myrcene, humulene, linalool, terpineol, geraniol, pinene, carene, citronellol, limonene, eucalyptol, sabinene, myrtenol, terpinene, camphene, borneol and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of hot flashes, facial flushing, night sweat, irritability, palpitation and tachycardia.

43. The product of Claim 42, further comprising a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate, biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

44. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of caryophyllene, pinene, myrcene, limonene, humulene, citronellol, eucalyptol, linalool, beta amyrin, cycloartenol, terpinene, terpineol, geraniol, carvacrol, thymol, cardinol, terpinene, menth-2-en-l-ol, carotol, humulene, nerolidol and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of inflammation, oxidative stress and paresthesia.

45. The product of Claim 44, further comprising a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, eugenyl acetate, piperine and combinations thereof.

46. The product of Claim 45, including caryophyllene wherein caryophyllene forms less than 5% by weight of the total terpene content.

47. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of linalool, camphene, limonene, pinene, borneol and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of cardiovascular disease, palpitation and tachycardia.

48. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of linalool, terpineol, pinene, carene, geraniol, thujone, camphor, viridiflorol, caryophyllene, germacrene, citronellol, eucalyptol, myrtenol, santalol, sabinene, limonene and combinations thereof, and wherein said condition and / or symptom comprises urine incontinence and / or lower urinary tract disorders.

49. The product of Claim 48, further comprising a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate and combinations thereof.

50. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, citronellol, limonene, myrcene, terpinene, menth-2-en-l-ol, eucalyptol, myrtenol and combinations thereof, and wherein said condition and / or symptom comprises vaginal dryness.

51. The product of Claim 50, further comprising a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate, biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

52. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of pinene, limonene, cymene, caryophyllene oxide, ocimene, nerolidol, eucalyptol, terpinene, terpineol, camphor, linalool, sabinene, thujone, viridiflorol, menthol, iso-menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, myrcene, menth-2-en-l-ol and combinations thereof, and wherein said condition and / or symptom comprises female urogenital and / or reproductive system infection. 53· The product of Claim 52, further comprising a compound selected from the group consisting of linally acetate, geranyl acetate, eugenol, eugenyl acetate, piperine, menthol, citronellyl formate and combinations thereof. 54• The product of Claim 1, wherein said at least one terpene is selected from the group consisting of linalool, terpineol, limonene, pinene, caryophyllene, caryophyllene oxide, terpinene, citronellol and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of fibroid, myomas and cysts in the female genital system. 55· The product of Claim 1, wherein said at least one terpene is selected from the group consisting of thujone, pinene, limonene, cymene, caryophyllene, caryophyllene oxide, eucalyptol, terpineol, sabinene, linalool, cardinol and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of cystitis, urethritis and pyelonephritis.

56. The product of Claim 55, further comprising eugenol. 57• The product of Claim 1, wherein said at least one terpene is selected from the group consisting of limonene, linalool, terpineol, geraniol, eucalyptol, pinene, citronellol and combinations thereof, and wherein said condition and / or symptom comprises reduced libido and / or sexual disfunction.

58. The product of Claim 57, further comprising a compound selected from the group consisting of biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

59. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of linalool, terpineol, eucalyptol, borneol, camphor, pinene, geraniol and combinations thereof, and wherein said condition and / or symptom comprises hair loss and / or thinning.

60. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of linalool, eucalyptol, geraniol, pinene, limonene and combinations thereof, and wherein said condition and / or symptom comprises brittle nails.

61. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of linalool, terpineol, geraniol, eucalyptol and combinations thereof, and wherein said condition and / or symptom comprises irregular body odor.

62. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of humulene, linalool, terpineol, caryophyllene, caryophyllene oxide, terpinene, citronellol, geraniol, thujone, camphor, viridiflorol, pinene, camphene, sabinene, myrcene, eucalyptol, carene, carotol, limonene, sabinene, cardinal, pinene and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of Polycystic Ovary Syndrome (POCS), amenorrhea, oligomenorrhea, hypermenorrhea, and metrorrhagia.

63. The product of Claim 62, further comprising a compound selected from the group consisting of linalyl acetate, geranyl acetate, eugenol, chamazulene, citronellyl formate and combinations thereof.

64. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of limonene, linalool, eucalyptol, nerolidol, sabinene, pinene, caryophyllene, terpineol, geraniol, thujone, camphor, viridiflorol, camphene, myrcene, caryophyllene, terpinene, carene, citronellol, carotol, neral, geranial and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of premenstrual syndrome (PMS), premenstrual tension, and premenstrual dysphoric disorder (PMDD).

65. The product of Claim 64, further comprising a compound selected from the group consisting of linally acetate, geranyl acetate, citronelly formate, menthol, eugenol, piperine, jasmone and combinations thereof.

66. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, camphene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, citronellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2-en- l-ol, carotol, sabinene, neral, geranial and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of hormonal disfunction, hormonal imbalance and fertility.

67. The product of Claim 66, further comprising a compound selected from the group consisting of linally acetate, geranyl acetate, chamazulene, citronelly formate, biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, sclareol, diosgenin, acetin, cimicifugoside and combinations thereof.

68. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of limonene, neral, geranial, caryophyllene, linalool, myrcene, nerolidol, fenchol, humulene, guaiol, borneol, cymene, terpinene and combinations thereof, and wherein said condition and / or symptom comprises pre-eclampsia toxemia.

69. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of linalool, terpineol, geraniol, thujone, camphor, viridiflorol, borneol, camphene, pinene, eucalyptol, caryophyllene, germacrene, pinene, carene, citronellol, nerol, farnesol, limonene, myrcene, terpinene, menth-2-en- l-ol, carotol, sabinene, neral, geranial, nerolidol, terpineol, carene and combinations thereof, and wherein said conditions and / or symptoms are associated with female hormonal disfunction and / or imbalance.

70. The product of Claim 69, further comprising a compound selected from the group consisting of biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof.

71. The product of Claim 1, wherein said at least one terpene is selected from the group consisting of caryophyllene, caryophyllene oxide, carene, linalool, myrcene, terpinene, terpineol, citronellol, eucalyptol, nerolidol, limonene, geraniol, menthol, iso-menthone, germacrene, pinene, cardinol, neral, geranial, menth-2-en-l-ol, pulegone, cymene, fenchol, humulene, guaiol, borneol, carene, sabinene, myrtenol, camphene, nerol, farnesol, carotol and combinations thereof, and wherein conditions and / or symptoms are associated with perimenopause and / or menopause.

72. The product of Claim 71, further comprising a compound selected from the group consisting of biochanin A, formononetin, genistein, daidzein, glycitein, prenylnaringenin, diosgenin, acetin, cimicifugoside and combinations thereof. 73• The product of Claim 1, wherein said at least one terpene is selected from the group consisting of myrcene, linalool, caryophyllene, eucalyptol, nerolidol, sabinene, humulene, terpineol, citronellol, geraniol, pinene, limonene, camphene, terpinene, borneol, camphor, menthone, iso-menthone, carvacrol, thymol, carene, nerol, farnesol, menth-2-en-l-ol, guaiol and combinations thereof, and wherein said condition and / or symptom comprises pain and / or cramps. 74• The product of Claim 1, wherein said at least one terpene is selected from the group consisting of myrcene, humulene, caryophyllene, linalool, terpineol, geraniol, pinene, germacrene, citronellol, limonene, myrcene, terpinene, menth-2-en-l-ol, borneol, eucalyptol, myrtenol, cymene, caryophyllene oxide, ocimene, nerolidol, camphor, sabinene, thujone, viridiflorol, menthol, iso- menthone, caryophyllene, germacrene, geraniol, nerol, neral, geranial, citronellol, carvacol, thymol, carene, myrtenol, carene, thujone and combinations thereof, and wherein said condition and / or symptom is selected from the group consisting of female urogenital infections, female urogenital disorders, reproductive system infections and reproductive system disorders. 75• The product of Claim 1, additionally containing an additive selected from the group consisting of antioxidants, emulsifiers, texturizers, vegetable oils, plant extracts, honey, sucrose, glucose, fructose, pharmaceutical excipients and combinations thereof.

76. The product as defined in Claim 1, produced by a method comprising providing at least one cannabinoid and blending it with at least one terpene and a non- cannabinoid, non-terpene carrier. 77• The product of Claim 76, said method including contacting cannabis plant material with an extractant to form an extract, wherein said extract comprises said at least one terpene.

78. The product of Claim 76, said method comprising synthesizing said at least one cannabinoid and blending said synthesized cannabinoid with said at least one terpene.

79. The product of Claim 76, said method comprising blending a cannabis plant material comprising said at least one cannabinoid with said at least one terpene.

80. The product of Claim 13, further comprising a herbal extract selected from the group consisting of extracts of angelica sinensis, cimicifuga (Actaea) racemosa, dioscorea villosa, trifolium pratense and combinations thereof.

81. The product of Claim 15, further comprising a herbal extract selected from the group consisting of extracts of avena sativa, cimicifuga (actaea) racemosa, humulus lupulus, hypericum perforatum, lavendula officinalis, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof.

82. The product of Claim 19, further comprising a herbal extract selected from the group consisting of extracts of avena sativa, bacopa monnieri, centella (Hydrocotyl) asiatica, humulus lupulus, hypericum perforatum, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof.

83. The product of Claim 23, further comprising a herbal extract selected from the group consisting of extracts of asphalentum ponjabianum - mumio, bacopa monnieri, centella (hydrocotyl) asiatica, eleutherococcus senticosus, ginkgo biloba, lepidium meyenii, lycium barbarum, paullinia cupana, rhodiola rosea and combinations thereof.

84. The product of Claim 26, further comprising a herbal extract selected from the group consisting of extracts of eleutherococcus senticosus, ganoderma lucidum, grifola frondosa, lentinula edodes, lepidium meyenii, panax ginseng, rhodiola rosea and combinations thereof.

85. The product of Claim 27, further comprising a herbal extract selected from the group consisting of extracts of glycyrrhiza glabra, plantago spp, symphytum officinalis, trifolium pratense, trigonella foenum graecum, ulmus rubra\fulva, verbascum thapsus and combinations thereof.

86. The product of Claim 29, further comprising a herbal extract selected from the group consisting of extracts of angelica sinensis, corydalis yanhusuo, piscidia erythrina, rosmarinus officinalis, stachys betonica, tanacetum parthenium, verbena officinalis and combinations thereof.

87. The product of Claim 31, comprising a herbal extract selected from the group consisting of extracts of ephedra sinica, foeniculum vulgare, fucus vesiculosus, garcinia cambogia, gymnema sylvestre, laminaria spp, paullinia cupana and combinations thereof.

88. The product of Claim 36, further comprising a herbal extract selected from the group consisting of extracts of cimicifuga (actaea) racemosa, paeonia lactiflora, viburnum opulus, viburnum opulus, vitex agnus castus and combinations thereof.

89. The product of Claim 39, further comprising a herbal extract selected from the group consisting of extracts of boswellia spp, capsicum spp, corydalis yanhusuo, harpagophytum procumbens, piscidia erythrina, salix alba, zingiber officinalis and combinations thereof.

90. The product of Claim 42, further comprising a herbal extract selected from the group consisting of extracts of angelica sinensis, anemarrhenae asphodeloides, cimicifuga (actaea) racemosa, dioscorea villosa, salvia officinalis, rehmania glutinosa preparata and combinations thereof.

91. The product of Claim 47, further comprising a herbal extract selected from the group consisting of extracts of cimicifuga (actaea) racemosa, crataegus spp, leonurus spp, passiflora incarnata and combinations thereof.

92. The product of Claim 48, further comprising a herbal extract selected from the group consisting of extracts of barosma betulina, equisitum arvense, plantago spp, urtica dioicanettle and combinations thereof.

93. The product of Claim 50, further comprising a herbal extract selected from the group consisting of extracts of dioscorea villosa spp, vitex agnus castus, withania somnifera, schisandra chinensis and combinations thereof.

94. The product of Claim 52, further comprising a herbal extract selected from the group consisting of extracts of anemarrhenae asphodeloides, cimicifuga (actaea) racemosa, coptis chinensis, echinacea spp, hydrastis canadensis and combinations thereof.

95. The product of Claim 54, further comprising a herbal extract selected from the group consisting of extracts of angellica sinesis, larrea mexicana, viburnum prunifolium, vitex agnus castus, trifolium and combinations thereof.

96. The product of Claim 55, further comprising a herbal extract selected from the group consisting of extracts of althea officinalis, andrographis paniculata, anemarrhenae asphodeloides, apium graveolens, arctostaphylos uva–ursi, barosma betulina, coptis chinensis, echinacea spp, hydrastis canadensis, plantago spp, uncaria tomentosa, zea mays and combinations thereof.

97. The product of Claim 57, further comprising a herbal extract selected from the group consisting of extracts of epimedium grandiflorum, ganoderma lucidum, lepidium meyenii, turnera diffusa, vitex agnus castus, withania somnifera and combinations thereof.

98. The product of Claim 59, further comprising a herbal extract selected from the group consisting of extracts of rehmania glutinosa preparata, rosmarinus officinalis, serenoa serrulata, urtica dioica and combinations thereof.

99. The product of Claim 62, further comprising a herbal extract selected from the group consisting of extracts of angelica sinensis, cimicifuga (actaea) racemosa, dioscorea villosa spp., vitex agnus castus, humulus lupulus, hypericum perforatum, lavendula officinalis, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof.

100. The product of Claim 64, further comprising a herbal extract selected from the group consisting of extracts of angelica sinensis, cimicifuga (actaea) racemosa, dioscorea villosa spp, paeonia lactiflora, vitex agnus castus and combinations thereof.

101. The product of Claim 66, further comprising a herbal extract selected from the group consisting of extracts of angelica sinensis, cimicifuga (actaea) racemosa, dioscorea villosa spp, trifolium pratense, vitex agnus castus and combinations thereof.

102. The product of Claim 68, further comprising a herbal extract selected from the group consisting of extracts of Crataegus spp, olea europea, passiflora incarnata and combinations thereof.

103. The product of Claim 69, further comprising a herbal extract selected from the group consisting of extracts of angelica sinensis, chamaelirium lutea, cimicifuga (actaea) racemosa, dioscorea villosa spp., trifolium pratense, vitex agnus castus and combinations thereof.

104. The product of Claim 71, further comprising a herbal extract selected from the group consisting of extracts of angelica sinensis, anemarrhenae asphodeloides, cimicifuga (actaea) racemosa, glycyrrhiza glabra, hypericum perforatum, panax quinquefolium, trifolium pratense, avena sativa, cimicifuga (actaea) racemosa, humulus lupulus, hypericum perforatum, lavendula officinalis, melissa officinalis, passiflora incarnata, valeriana officinalis and combinations thereof.

105. The product of Claim 73, further comprising a herbal extract selected from the group consisting of extracts of angelica sinensis, piscidia erythrina, tanacetum parthenium, viburnum opulus, boswellia spp, capsicum spp, corydalis yanhusuo, harpagophytum procumbens, rosmarinus officinalis, salix alba, zingiber officinalis and combinations thereof.

106. The product of Claim 74, further comprising a herbal extract selected from the group consisting of extracts of apium graveolens, dioscorea villosa spp, althea officinalis, anemarrhenae asphodeloides, anemarrhenae asphodeloides, apium graveolens, arctostaphylos uva-ursi, barosma betulina, coptis chinensis, echinacea spp, equisitum arvense, hydrastis canadensis, plantago spp, serenoa serrulata, uncaria tomentosa, urtica dioica, viola tricolor, zea mays and combinations thereof.